JPS647044B2 - - Google Patents
Info
- Publication number
- JPS647044B2 JPS647044B2 JP54049830A JP4983079A JPS647044B2 JP S647044 B2 JPS647044 B2 JP S647044B2 JP 54049830 A JP54049830 A JP 54049830A JP 4983079 A JP4983079 A JP 4983079A JP S647044 B2 JPS647044 B2 JP S647044B2
- Authority
- JP
- Japan
- Prior art keywords
- tyrosine
- amount
- brain
- dopamine
- norepinephrine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 117
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 117
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 101
- 210000004556 brain Anatomy 0.000 claims description 87
- 229960003638 dopamine Drugs 0.000 claims description 50
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims description 45
- 229960002748 norepinephrine Drugs 0.000 claims description 45
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims description 44
- 150000001413 amino acids Chemical class 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 31
- 210000000225 synapse Anatomy 0.000 claims description 26
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 21
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 21
- 230000000694 effects Effects 0.000 claims description 19
- 230000007935 neutral effect Effects 0.000 claims description 16
- 230000007423 decrease Effects 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 14
- 210000002569 neuron Anatomy 0.000 claims description 12
- 230000003247 decreasing effect Effects 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- 230000007812 deficiency Effects 0.000 claims description 3
- 230000003291 dopaminomimetic effect Effects 0.000 claims description 3
- 230000036470 plasma concentration Effects 0.000 claims description 3
- 230000007830 nerve conduction Effects 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 48
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 37
- QRMZSPFSDQBLIX-UHFFFAOYSA-N homovanillic acid Chemical compound COC1=CC(CC(O)=O)=CC=C1O QRMZSPFSDQBLIX-UHFFFAOYSA-N 0.000 description 36
- 229940024606 amino acid Drugs 0.000 description 33
- 241000700159 Rattus Species 0.000 description 26
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 26
- 229960003081 probenecid Drugs 0.000 description 26
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 26
- 238000012360 testing method Methods 0.000 description 23
- 229960003878 haloperidol Drugs 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 16
- 229940076279 serotonin Drugs 0.000 description 13
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 12
- 238000009825 accumulation Methods 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 11
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 235000005911 diet Nutrition 0.000 description 9
- 230000037213 diet Effects 0.000 description 9
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 8
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 210000001577 neostriatum Anatomy 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000005018 casein Substances 0.000 description 6
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 6
- 235000021240 caseins Nutrition 0.000 description 6
- 239000002858 neurotransmitter agent Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- XQQUKAGHLDAJGO-UHFFFAOYSA-N 1-(2,6-dihydroxy-4-methoxyphenyl)hexan-1-one Chemical compound CCCCCC(=O)C1=C(O)C=C(OC)C=C1O XQQUKAGHLDAJGO-UHFFFAOYSA-N 0.000 description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- 208000018737 Parkinson disease Diseases 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 230000007306 turnover Effects 0.000 description 4
- 239000004474 valine Substances 0.000 description 4
- FBWPWWWZWKPJFL-UHFFFAOYSA-N 3-Methoxy-4-hydroxyphenylethyleneglycol Chemical class COC1=CC(C(O)CO)=CC=C1O FBWPWWWZWKPJFL-UHFFFAOYSA-N 0.000 description 3
- 102000015554 Dopamine receptor Human genes 0.000 description 3
- 108050004812 Dopamine receptor Proteins 0.000 description 3
- 208000028017 Psychotic disease Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 3
- 150000002871 norepinephrines Chemical class 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000012661 Dyskinesia Diseases 0.000 description 2
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 2
- 208000016285 Movement disease Diseases 0.000 description 2
- 208000000323 Tourette Syndrome Diseases 0.000 description 2
- 208000016620 Tourette disease Diseases 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 235000015115 caffÚ latte Nutrition 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 150000003943 catecholamines Chemical class 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000005064 dopaminergic neuron Anatomy 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 230000008713 feedback mechanism Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N βâMercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- RQPKNXVVIBYOBX-KDBLBPRBSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-2-(dihydroxyamino)-3-phenylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.ON(O)[C@H](C(O)=O)CC1=CC=CC=C1 RQPKNXVVIBYOBX-KDBLBPRBSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- GIHYTRGUZVYCQX-UHFFFAOYSA-N 2-amino-6,7-dimethyl-5,6,7,8-tetrahydro-1h-pteridin-4-one;hydron;chloride Chemical compound Cl.N1C(N)=NC(=O)C2=C1NC(C)C(C)N2 GIHYTRGUZVYCQX-UHFFFAOYSA-N 0.000 description 1
- UQTZMGFTRHFAAM-ZETCQYMHSA-N 3-iodo-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(I)=C1 UQTZMGFTRHFAAM-ZETCQYMHSA-N 0.000 description 1
- WUFPNASKMLJSND-UHFFFAOYSA-N 3-methoxy-4-hydroxyphenylethyleneglycol sulfate Chemical compound COC1=CC(C(O)CO)=CC=C1OS(O)(=O)=O WUFPNASKMLJSND-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000003823 Aromatic-L-amino-acid decarboxylases Human genes 0.000 description 1
- 108090000121 Aromatic-L-amino-acid decarboxylases Proteins 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 102000004031 Carboxy-Lyases Human genes 0.000 description 1
- 108090000489 Carboxy-Lyases Proteins 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000027219 Deficiency disease Diseases 0.000 description 1
- 206010054089 Depressive symptom Diseases 0.000 description 1
- 108010015720 Dopamine beta-Hydroxylase Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical class O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex⢠Substances 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004469 amino acid formulation Substances 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940082992 antihypertensives mao inhibitors Drugs 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- FFSAXUULYPJSKH-UHFFFAOYSA-N butyrophenone Chemical compound CCCC(=O)C1=CC=CC=C1 FFSAXUULYPJSKH-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000002925 chemical effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000002816 gill Anatomy 0.000 description 1
- 229940095895 haldol Drugs 0.000 description 1
- 235000008085 high protein diet Nutrition 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 150000002990 phenothiazines Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 235000021195 test diet Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
- XREXPQGDOPQPAH-QKUPJAQQSA-K trisodium;[(z)-18-[1,3-bis[[(z)-12-sulfonatooxyoctadec-9-enoyl]oxy]propan-2-yloxy]-18-oxooctadec-9-en-7-yl] sulfate Chemical compound [Na+].[Na+].[Na+].CCCCCCC(OS([O-])(=O)=O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(CCCCCC)OS([O-])(=O)=O)COC(=O)CCCCCCC\C=C/CC(CCCCCC)OS([O-])(=O)=O XREXPQGDOPQPAH-QKUPJAQQSA-K 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
æ¬çºæã¯ãç¥çµã·ããã¹ïŒããŠãŒããã«ã·ãã
ã¹ïŒäžã®ãããã³ããã³ãã«ãšããããªã³ã®éã
å¶åŸ¡ïŒå¢å€§ãŸãã¯äœäžïŒãåŸãçµæç©ã«é¢ããã
ã®ã§ããã ç¥çµäŒéç©è³ªã§ãããããã³ããã³ãã«ãšãã
ããªã³ããžããããã·ããšãã«ã¢ã©ãã³ïŒããïŒ
ããèªå°ãããç©è³ªã§ããããšã¯æ¢ã«å ¬ç¥ã§ã
ããäžæ¹ãããã¯ãã¢ããé žã§ããããã·ã³ã®é µ
çŽ åŠçããããã·ã«åã«ãããã€ãã³äžã§çæã
ããã®ã§ããããã®ããã»ã¹ã¯ãé µçŽ ã§ãããã
ã·ã³ããããã·ã©ãŒãŒã®è§Šåªäœçšã®ããšã§é²è¡ã
ããããã¯ãé µçŽ ã§ããâã¢ããé žãã«ã«ãã
ã·ã©ãŒãŒïŒAAADïŒã«ããè±ã«ã«ããã·ã«åã
ããŠãããã³ã«ãªãããã«ãšããããªã³ã¯ãé µçŽ
ã§ãããããã³âβâããããã·ã©ãŒãŒããå«ã
ãã€ãã³äžã§ãããã³ããçããããã®äžé£ã®å
å¿ã«ãããŠãåŸé段éã¯ããã·ã³ãããããžã®å€
æ段éã§ããããã®çç±ã®ããã«ãããŒãã³ãœã³
ç ã®åŠããããã³æ¬ ä¹æ§çŸç ã«èµ·å ãã身äœé害
éšãæããæ£è ã«ãããã³æäžãè¡ãããããšã
ãã€ããããããªããéœåã®æªãããšã«ã¯ããã
ãæäžãããšããã¯èº«äœå šäœã®çŽ°èã«åžåãããŠ
ãããã³ã«å€ãããããã«ãã€ãŠããããã®çŽ°è
ã«ãããæ£åžžãªä»£è¬ããã»ã¹ã劚害ããããšãã
äžéœåãªäºæ ãçããã®ã§ãããããã«ããã¯ã
ç¥çµäŒéç©è³ªã§ããã»ãããã³ã®æ£åžžãªäººäœå è
ç©ã劚害ãããã€ãâã¢ããã·ã«ã¡ããªãã³å
åç©ã®è³å ååšéãäœäžãããããããã®äžææ
ã®å¯äœçšã®ããã«æ£è ã«ããããããªã³âãªãçŸ
象ãçãèªããããããšãããããããŠæå Žåã«
ã¯ç²Ÿç¥ç ç城åãèªããããããšããããåŸãã
ã·ããã¹äžã®ãããã³ããã³ãã«ãšããããªã³ã®
éãå¢å ãããäœçšãæããä»çš®è¬å€ã®äŸã«ã¯ã¢
ãã¢ãã³ãªãã·ããŒãŒæå¶å€ïŒããã¯åèšã®ç¥çµ
äŒéç©è³ªã®å解ãé 延ããããã®ã§ããïŒããã³
ïŒæ žåã®ææãã€å€ïŒã¢ã³ãããã¬ãµã³ãïŒãã
ããããããããã®ååç©ã¯æå§çç¶ã䌎ãçŸç
ã®æ²»çå€ãšããŠäœ¿çšãããŠãããããããããŸ
ããã·ããã¹äžã®ãããã³ããã³ãã«ãšããããª
ã³ã®éã®å¢å äœçšã®ä»ã«æ¯èŒçéç¹ç°æ§ã®ååŠç
äœçšãæãããã®ã§ãã€ãŠãããªãã¡çš®ã ã®å¯äœ
çšãæããããšãã°è¡å§äžæäœçšçãæãããã
ãããŠãã®è¡å§äžæã¯ã¢ãã¢ãã³ãªãã·ããŒãŒæ
å¶å€ãæäžããæ£è ãæçš®ã®é£åãé£ã¹ããšãç
ã«èµ·ããã®ã§ããã ã·ããã¹äžã«ãããã³ãŸãã¯ãã«ãšããããªã³
ãéå°éååšãããšãã«èµ·ãä»çš®çŸç ã®äŸã«ã¯æ¬¡
ã®ãã®ããããããïŒç²Ÿç¥ç ïŒãããã³ã®éã極
端ã«å€ãïŒãéåé害çïŒmovement disordersïŒ
ããšãã°ã¿ãŒãžãã»ãžã¹ããã·ã¢çããã³ã®ã¬
ã¹ãããã©ãããŠã¬ããçå矀ïŒãããã³ã®éã
極端ã«å€ãïŒïŒé«è¡å§ããã³äžæŽèïŒäº€æç¥çµã
ã€ãã³ããæŸåºããããã«ãšããããªã³ã®éã極
端ã«å€ãïŒãçŸåšãããã®ç æ°ã®æ²»çã¯äžè¬ã«ã
ãããã³ãŸãã¯ãã«ãšããããªã³ãšãã®åŸæã¬ã»
ãã¿ãŒïŒpostâreceptorsïŒãšã®ã€ã³ã¿ãŒã©ã¯ã·
ãšã³ã劚害ããè¬å€ïŒããšãã°ããšããã¢ãžã³ãŸ
ãã¯ãããããšãã³ïŒãçšããŠè¡ãããŠãããã
ãããªãããããã®è¬å€ã¯ãã¹ãŠãè¥å¹²ã®éç¹ç°
æ§äœçšãè¡šãããã®ã§ãã€ãŠããããã€ãŠãã®æ
çšæã«å¯äœçšãè¡šãããããšãããã ç¥çµäžã®ããã·ã³ã®éãå€ããããšã«ãããã
ãã³ãŸãã¯ãã«ãšããããªã³ã®éãå¢å ãŸãã¯æž
å°ãããè©Šã¿ã以åã«è¡ããããããã®è©Šã¿ã¯æ
åããªãã€ãããªããªãã°è³ããã³çš®ã ã®çµç¹ã®
äžã®ãããã®ååç©ã®éãå€åãããããšã¯è¡ã
ããªãã€ãããã§ãããè³å ã®ããã®æ¿åºŠã¯ãæ
å®ã®å®éšæ¡ä»¶äžã§ã¯ãããã³ããã³ãã«ãšããã
ãªã³ã®åæé床ã«æ¯äŸããŠå€åãããããŠè³å ã®
ããã®æ¿åºŠã¯ãè³å ã®ããã·ã³ã®æ¿åºŠã®å¢å ã«ã
ãå¢å ãããããšãã§ãããã€ãè³å ã®ããã®æ¿
床ã¯ãè³å ã®ããã·ã³ã®æ¿åºŠãäœäžãããããšã
ã§ããïŒã©ãããçšããå®éšïŒããšãæåã«èŠåº
ããç 究è ã¯ã¯ãŒããã³çã§ããïŒããµã€ãšã³ã¹ã
第185巻第183é â第184é ïŒ1974幎ïŒæ12æ¥ïŒãã
è³å ã®ããã·ã³ã®éãå¢å ãããããã®ãåŠçæ¹
æ³ã®ïŒã€ã¯ãããã·ã³ããèªäœãæäžããããšã§
ãã€ããè³å ã®ããã·ã³ã®éãæžå°ãããããã®
åŠçæ¹æ³ã®ïŒã€ã¯ãè¡æŒ¿äžã®ããã·ã³ïŒãã©ãºã
ããã·ã³ïŒã®è³å 移è¡æ§ãšç«¶åããæ§è³ªãæãã
ä»çš®äžæ§ã¢ããé žã®ãã¡ã®ïŒã€ïŒããšãã°ãã€ã·
ã³ïŒãæäžããããšã§ããããã®åŠèª¬ãçºè¡šãã
ã以åã«ã¯ãåèšã®åŸé段éã®åå¿ãé²è¡ããã
é µçŽ ã§ããããã·ã³ããããã·ã©ãŒãŒã¯ããã·ã³
ã«ããé«åºŠé£œåç¶æ ã«ãªã€ãŠããã®ã§ãè³å ã®ã
ãã·ã³ã®éã®å¢å ãŸãã¯æžå°ãããã·ã³ãããã
ãžã®å€æåå¿ã«åœ±é¿ãäžããããšã¯ãªãã§ããã
ãšæãããŠããã®ã§ãããäžæ¹ãäžèšã®ã¯ãŒãã
ã³çã®è«æãŸãã¯å ¶åŸã«çºè¡šãããã®ããœã³åã³
ã¯ãŒããã³è«æããBiochem.Pharmacologyã第
26巻第1137é â第1142é ïŒ1977幎ïŒæå·ïŒãã«ã¯ã
ããèç©éã«é¢ããåèšã®å€åã¯ãè³å ã®ããã
ã³ãŸãã¯ãã«ãšããããªã³ã®éã®å€åã«äŒŽããã®
ã§ããããšã¯å šãé瀺ãããŠããªãããŸãè³å ã®
ããã·ã³ã®éãå€ããããšã«ãããã·ããã¹ãžã®
ãããã³ãŸãã¯ãã«ãšããããªã³ã®æŸåºéã«åœ±é¿
ãäžããããšãã§ããããšãäžèšã®æç®ã«ã¯å šã
é瀺ãããŠããªãã ã·ããã¹äžã«å®éã«ååšãããããã³ããã³ïŒ
ãŸãã¯ãã«ãšããããªã³ã®éãå¢å ãŸãã¯æžå°ã
ããæ段ãéçºããããšã¯ãéåžžã«å¥œãŸããããš
ã§ããããã€ãã³äžã«è²¯èµãããååŠäŒéç©è³ª
ïŒããªãã¡ã·ããã¹äŒéç©è³ªïŒã®ãã¹ãŠã®ååã
çããã·ããã¹ã«å®¹æã«æŸåºã§ãããã®ãšã¯éã
ãªããšããããšãçŸåšå ¬ç¥ã§ãããããã·ããã¹
äžã§ã®è©²ååŠäŒéç©è³ªã®éçå€åã«äŒŽã€ãŠãè³ãŸ
ãã¯ä»ã®çµç¹ã®äžã®ãããã³ãŸãã¯ãã«ãšããã
ãªã³ã®å šéãå€åãããšã¯éããªããåèšã®ã
ããMAOæå¶å€ãããšããã¢ãžã³ããã³ä»ã®è¬
å€ã®æäžæã«äŒŽããããªäžææã®å¯äœçšããªãã
ãã€çååŠçç¹ç°æ§ãæãããããªæ段ãéçºã
ãã®ãæãŸããã®ã§ããããã®ãããªæ段ã¯ãã
ãèªäœãçš®ã ã®ç æ°ã®ããã®æçšãªæ²»çæ段ãšã
ãŠå©çšã§ããã§ãããããããã¯ãçš®ã ã®è¬å€ã®
æ²»çå¹æãäžå±€é«ããããã«ãåèšã®æ段ã¯è©²è¬
å€ãšçµåãããŠå©çšã§ããã§ãããã æ¬çºæã¯ãã·ããã¹äžã®ãããã³ããã³ïŒãŸã
ã¯ãã«ãšããããªã³ã®äžè¶³ãŸãã¯éå°åã䌎ãç
æ°ãæ²»çããããã®çµæç©ãæäŸãããã®ã§ã
ããç¥çµäžã®ããã·ã³ã®éãå¢å ãŸãã¯æžå°ãã
ããããªåŠçã¯ãã·ããã¹äžãžã®ãããã³ãŸãã¯
ãã«ãšããããªã³ã®æŸåºéã®å¢å ãŸãã¯æžå°ãã
ããããã®ã§ãããããããŠåŸè ã®å Žåã®å¢å é
ãŸãã¯æžå°éã¯ãããããåè ã®å Žåã®å¢å éãŸ
ãã¯æžå°éã«å¯Ÿå¿ããå€ã§ããããšãæ¬çºæè ã
æ€åºŠèŠåºãããã®çºèŠã«åºããŠæ¬çºæãå®æãã
ãã®ã§ãããããã·ã³ããã®ãã¬ã«ãŒãµãŒïŒåé§
äœïŒãããšãã«ã¢ã©ãã³ãŸãã¯ä»ã®äžæ§ã¢ããé ž
ã¯åç¬ãŸãã¯æ··åç©ã®åœ¢ã§ããã€ä»ã®è¬å€ãšäžç·
ã«ããŸãã¯äžç·ã«ããã«æäžã§ããããã«ãã€
ãŠãè³å ã®ããã·ã³ïŒããã³ããšãã«ã¢ã©ãã³ïŒ
ã®éãå¢å ãŸãã¯æžå°ãããããšãã§ããããã
ãã®æäžã«ãã€ãŠãã·ããã¹äžã®ãããã³ãã
ã³ïŒãŸãã¯ãã«ãšããããªã³ã®äžè¶³ãŸãã¯éå°ã«
èµ·å ããç æ°ãæ²»çã§ãããåæ§ã«ãåèšæ··åç©
äžã®ããªãããã¢ã³ãŸãã¯ä»ã®ã¢ããé žã®ååšå²
åãçš®ã å€ããããšã«ãããè³å ã®ã»ãããã³ãŸ
ãã¯ä»ã®ç¥çµäŒéç©è³ªã®åæéããã³ã·ããã¹ãž
ã®ãã®æŸåºéã調ç¯ã§ããããããã³æŸåºæ§ãã€
ãã³ãæ¬æ§ç¶æ ã«ãªã€ãŠããå Žåãããªãã¡ãã
ã°ãã°è奮ãããããªå Žåã«ã¯ãããã·ã³ãã
ã³ïŒãŸãã¯ããšãã«ã¢ã©ãã³ã®æäžåŸã«ã·ããã¹
äžã®ãããã³ã®éãå¢å ããã§ãããããã«ãšã
ãããªã³æŸåºæ§ãã€ãã³ãç¹ã«é«æŽ»æ§ã®ãã®ã§ã
ããåŠããšããããšãšã¯ç¡é¢ä¿ã«ãããã·ã³ã®æ
äžã«ããã·ããã¹äžã®ãã«ãšããããªã³ã®éãå¢
å ãããããšãã§ãããããã·ã³å«æéã®äœãäž
æ§ã¢ããé žè£œå€ïŒããªãã¡äžæ§ã¢ããé žçµæç©ïŒ
ãæäžããŠè³å ã®ããã·ã³ã®éãæžå°ãããããš
ã«ãããã·ããã¹äžãžã®ãããã³ããã³ãã«ãšã
ãããªã³ã®æŸåºéãæžå°ãããããšãã§ãããå
æ§ã«ãè³å ã®ããªãããã¢ã³ã®éãæžå°ãããã
ãšã«ãããã»ãããã³ã®æŸåºéãäœäžãããããš
ãã§ãããæå®ã®äžæ§ã¢ããé žæ··åç©ã®äžã®ãã
ã·ã³ã®ååšæ¯çã調æŽããããšã«ããããããã³
ããã³ïŒãŸãã¯ãã«ãšããããªã³ã®æŸåºéãå¢å
ãŸãã¯æžå°ãããããšãã§ãããå°éæäžã®å Žå
ã«ã¯ãããã·ã³ã®ä»£ãã«ããšãã«ã¢ã©ãã³ã䜿çš
ããããšãã§ãããåŸèšã®åŠãããããã³ããã³
ãã«ãšããããªã³ã®æŸåºéã調ç¯ããªããã·ãã
ã¹ãžã®ã»ãããã³ã®æŸåºéã調ç¯ããããã«ãå
èšäžæ§ã¢ããé žæ··åç©äžã«ååšããããªãããã¢
ã³ã®éšåããå©çšããããšãã§ããã æ¬çºæã«åŸãã°ãããã·ã³ããã³ïŒãŸãã¯ããš
ãã«ã¢ã©ãã³ããã³ïŒãŸãã¯ä»ã®äžæ§ã¢ããé žã
åç¬ã§ããŸãã¯ïŒçš®ãŸãã¯ãã以äžã®è¬å€ãšçµå
ãããŠæ£è ã«æäžãããããã«ãã€ãŠãã·ããã¹
ãžã®ãããã³ããã³ïŒãŸãã¯ãã«ãšããããªã³ã®
æŸåºéãå¢å ãŸãã¯æžå°ãããããšãã§ãããå
æã«ãåèšã¢ããé žæ··åç©äžã®ããªãããã¢ã³ã®
ååšæ¯çãçš®ã å€ããããšã«ãããã»ãããã³ã®
æŸåºéã調ç¯ã§ããããããã³ã®æŸåºéãå¢å ã
ããããã«ã¯ãããŒãã³ãœã³ç æ£è ã®å Žåã®ãã
ã«æ£è ã®è³ã®äžã®ãããã³æŸåºæ§ãã€ãã³ã¯æ¯èŒ
çé«æŽ»æ§ã®ãã®ãããªãã¡ã²ãã±ãã«è奮ããã
ã®ã§ããããšãå¿ èŠã§ãããããããªããããã«
ãšããããªã³æŸåºæ§ãã€ãã³ãŸãã¯ã»ãããã³æŸ
åºæ§ãã€ãã³ãç¹ã«é«æŽ»æ§ã®ãã®ã§ãã€ãŠããªã
ãŠãããã®ããšãšã¯ç¡é¢ä¿ã«ãã¢ããé žæ··åç©ã®
䜿çšã«ããã·ããã¹äžãžã®ãã«ãšããããªã³ãŸã
ã¯ã»ãããã³ã®æŸåºéãçš®ã å€ããããšãã§ãã
ã®ã§ãããåæ§ã«ãè³å ã«å ¥ãããã·ã³ãšç«¶åã
åŸããããªã¢ããé žæ··åç©ãæäžããããšã«ã
ãããããã³ãŸãã¯ãã«ãšããããªã³ã®æŸåºéã
æžå°ãããããšãã§ããã ããã§äœ¿çšãããã¢ããé žæ··åç©ã®çµæã¯ãæ²»
çãã¹ãæ£è ã®ç æ°ã®çš®é¡ïŒçç¶ïŒã«å¿ããŠçš®ã
å€ããããšãã§ãããã»ãããã³ã®æŸåºéãå¢å
ãããããšãªããããã³ããã³ïŒãŸãã¯ãã«ãšã
ãããªã³ã®æŸåºéãå¢å ãããå¿ èŠãããå Žåã«
ã¯ãããã·ã³ïŒããã³ïŒãŸãã¯ããšãã«ã¢ã©ã
ã³ïŒããã»ãããã³ã®åé§äœã§ããããªãããã¢
ã³ãå«ãŸãªãä»çš®ã¢ããé žé¡ãšäžç·ã«ããŸãã¯äž
ç·ã«ããã«æäžããããšãã§ãããã®æäžéã¯ïŒ
â200mgïŒKgã§ããåŸãããã®æ²»çæ³ã¯åç¬æ²»ç
æ³ãšããŠããããã¯å¥ã®è¬å€æäžæ²»çæ³ã®è£å©ç
æ³ãšããŠãããšãã°æ¬¡ã®ç æ°ã«æå¹ã§ããïŒããŒ
ãã³ãœã³ç ïŒæçš®ã®æå§çç¹ã«é«è¡å§ïŒæ«æ¢¢äº€æ
ç¥çµç³»ã®æ©èœæå·ã«ããäœè¡å§ïŒãªã«ãœã¹ã¿ãã
ã¯äœè¡å§ïŒãæå Žåã«ã¯ãããã·ã³ã®ä»£çšç©ãšã
ãŠããšãã«ã¢ã©ãã³ã䜿çšã§ããããªããªãã°ã
ã®ã¢ããé žã¯èèå ã§ããã·ã³ã«å€æããããã
ãŠè¡æ¶²æµã®äžã«æŸåºãããè³ã®äžã«å ¥ãããã§ã
ããããããªãããè¡æŒ¿äžã®ããšãã«ã¢ã©ãã³ã®
æ¿åºŠã¯ãããã·ã³ã®æ¿åºŠã®çŽïŒåãããäœãå€ã§
ããã¹ãã§ããããªããªãã°ããã®ãããªé«ãæ¿
床ã§ã¯è³å 移è¡ã«é¢ããŠããšãã«ã¢ã©ãã³ã¯ãã
ã·ã³ãšç«¶åããããã·ã³ããããã·ã©ãŒãŒé µçŽ ã®
äœçšã劚害ããããšãããåŸãããã§ããã è³å ã®ã»ãããã³ã®éããã®ãŸãŸç¶æããããŸ
ãã¯å¢å ãããªãããããã³ãŸãã¯ãã«ãšããã
ãªã³ã®æŸåºéãå¢å ãããå¿ èŠãããå Žåã«ã¯ã
ããã·ã³ããã³ïŒãŸãã¯ããšãã«ã¢ã©ãã³ããã³
ä»çš®äžæ§ã¢ããé žã®ä»ã«ããã«ããªãããã¢ã³ã
ãå«ãçµæç©ã䜿çšããã®ãããããã®ãããªçµ
æç©ïŒãŸãã¯äžèšã¢ããé žã®çµåãïŒã¯ãæçš®ã®
æãã€ç¶æ ãŸãã¯ç¡ç é害ã®æ²»çå€ãšããŠç¹ã«æ
çšã§ãããäžèšã«äŸç€ºããçµæç©ãå«æãåŸãã¢
ããé žä»¥å€ã®äžæ§ã¢ããé žã®äŸã«ã¯åæç¶ã¢ãã
é žïŒãã€ã·ã³ãã€ãœãã€ã·ã³ãããªã³ïŒããã³ã¡
ããªãã³ãã¹ã¬ãªãã³ããã¹ããžã³ããããã
ãããããã®ã¢ããé žã¯åéäœãŸãã¯å€©ç¶ãŸãã¯
åæéåäœïŒããšãã°ããããïŒã®åœ¢ã§æäžã§ã
ãã以äžã®èšèŒã§ã¯ãããšãã«ã¢ã©ãã³ãããªã
ããã¢ã³ããã³ããã·ã³ãæçšã¢ããé žããšç§°ã
ãããšã«ããã ããšãã°ç²Ÿç¥ç ãéåé害çïŒããšãã°ã¿ãŒãž
ãã»ãžã¹ããã·ã¢çãŸãã¯ã®ã¬ã¹ãããã©ãããŠ
ã¬ããçå矀ïŒçã®ç æ°ãããªãã¡ãããããŒãž
ãã¯ïŒdopaminergicïŒãã€ãã³ãå€åè¶ æŽ»æ§ç¶
æ ã«ãªã€ãŠããç æ°ã§ã¯ãã·ããã¹äžã®ãããã³
ã®éãæžå°ãããå¿ èŠããããããã®ãããªå Žå
ã«ã¯ãããã·ã³ãŸãã¯ããšãã«ã¢ã©ãã³ãå šãå«
ãŸãªãããŸãã¯æ¯èŒçå°éããå«ãŸãªãäžæ§ã¢ã
ãé žæ··åç©ãæäžããããããšåæ§ãªæ··åç©ã¯ã
ã·ããã¹äžã®ãã«ãšããããªã³ã®éãæžå°ããã
ããã«äœ¿çšã§ãããã€ãŸããã·ããã¹ã®ããªãã
ãã¢ã³å«æéã«å¿ããŠã·ããã¹äžã®ã»ãããã³ã®
éãå¢å ãŸãã¯æžå°ãããããã«ã䜿çšã§ããã ããã·ã³ãããšãã«ã¢ã©ãã³ããã³ããªããã
ã¢ã³ã®è¡æŒ¿äžæ¿åºŠãšãä»ã®äžæ§ã¢ããé žå šäœã®è¡
挿äžæ¿åºŠãšã®æ¯çã¯é£ç©ã®çµæã«å·Šå³ããããã
æ£åžžæã®ãã®æ¯ã®å€ã¯äžè¬ã«ããããçŽ0.08â
0.12ãçŽ0.07â0.12ããã³çŽ0.06â0.14ã§ãããæ
çš®ã®ç æ°ã®å Žåã«ã¯ãããšãã°ãæç¡ãæãè硬
å€ãç³å°¿ç ãã€ã³ã·ãŠãªã³éå°ç
ïŒhyperinsulinismïŒãç°åçç¶ïŒé£¢é€ãæªæ¶²è³ªã
åºãã€ãã¬ã³ïŒãã²ã©ãç«å·ãŸãã¯å€å·çã®ç æ°
ã®å Žåã«ã¯ãäžèšã®æ¯ã®å€ãç°åžžå€ã«ãªããè³ã«
ããããããã³ããã«ãšããããªã³ããã³ã»ãã
ãã³ã®æŸåºéã®å€åãããããããã®ãããªå Žå
ã«äœ¿çšãããã¢ããé žçµæç©ã¯ãåèšã®è¡æŒ¿äžæ¿
床ã®å€ãæ£åžžå€ã«æ»ãã®ã«é©ããçµæãæããã
ã®ã§ããã¹ãã§ãããäžèšã«äŸç€ºãããããªäž»ãš
ããŠç²Ÿç¥ç¥çµççç¶ã䌎ãç æ°ã®å Žåã«ã¯ããã®
ã¢ããé žçæ³ã®ç®æšã¯ãã·ããã¹äžãžã®ãããã³
ãŸãã¯ãã«ãšããããªã³ïŒãŸãã¯ã»ãããã³ïŒã®
æŸåºéãå¢å ãŸãã¯æžå°ãããããã«ãåèšã®æ¯
ã®å€ïŒããã¯çœ¹ç æã«ã¯åèšã®æ£åžžç¯å²å ã®å€ã
ããé«ãããŸãã¯äœãå€ã«ãªã€ãŠããïŒãäœãã
ããŸãã¯é«ããããšã§ããã ããã·ã³ãããšãã«ã¢ã©ãã³ããã³ä»ã®äžæ§ã¢
ããé žã¯ãéé¢ã¢ããé žããã®ãšã¹ãã«ãå¡©ã倩
ç¶ãŸãã¯åæéåäœã®åœ¢ã§æäžã§ãããããã¯é£
åã®æ§ææåã®åœ¢ã§æäžã§ããããã®æäžã¯çµå£
æäžãŸãã¯éçµå£æäžïŒããšãã°éèå 泚å°ïŒã®
圢ã§è¡ãããšãã§ããã æ¬çºæãäžå±€å ·äœçã«äŸç€ºããããã«ã次ã«å®
æœäŸã瀺ããããããªããæ¬çºæã®ç¯å²ã¯æ±ºããŠ
ãããã®å®æœäŸã«èšèŒã®ç¯å²å ã®ã¿éå®ãããã
ã®ã§ã¯ãªãã äŸ ãã®å®æœäŸã¯ãè³å ã§ãã«ãšããããªã³ãè³å
ã®ããã·ã³ã®éãå¢å ãããããšã«ããåæã§ã
ãããšãäŸç€ºãããã®ã§ããã ãã®å®æœäŸäžã®å®éšããŒã¿ãŒã«ç€ºãããŠããã
ãã«ãè³å ã®ãã«ãšããããªã³ã®äž»ä»£è¬ç£ç©ã§ã
ãïŒâã¡ããã·âïŒâããããã·âããšãã«ãšã
ã¬ã³ã°ãªã³ãŒã«âãµã«ããšãŒãïŒMOPEGâ
SO4ïŒãã©ããã®è³å ã«èç©ãããšãã®èç©é床
ã¯ãè³å ã®ããã·ã³ã®éã®é¢æ°ã®åœ¢ã§çš®ã å€åã
ããã®ã§ããããã®ããšããæãããªããã«è³å
ã®ããã·ã³ã®éã¯ãè³å ã®ãã«ãšããããªã³ã®å
æéã®ã¿ãªããããã®ãã«ãšããããªã³ã®ã¿ãŒã³
ãªãŒããŒéããã³æŸåºéã«ã圱é¿ãäžãããã®ã§
ããã äœé150ïœã®ãªã¹ã®ã¹ãã©ã°ãŒâããŒã¬ã€ã©ã
ãããã€ãŒã«ã¹ããªããŒãããªãŒãžã³ã°ãã©ãã©
ããªãŒãºïŒãŠã€ã«ãã³ã°ãã³ãMAïŒããäŸçµŠã
ãããã®ãããã€ãããããã«å ¥ããŠé£Œè²ãã
ïŒïŒããåœãïŒâïŒå¹ïŒããããŠé£²ææ°Žããã³26ïŒ
èçœè³ªé£ŒæïŒãã€ãŒã«ã¹ããªããŒãã©ããâããŠ
ã¹âãã ã¹ã¿ãŒãã¡ã€ã³ããã³ã¹ãããªãŒããŠã©
ãŒ24RFïŒãèªç±ã«äžãããæ¯æ¥ååïŒæããå
åŸïŒæãŸã§å ç·ã300ãã€ã¯ãã¯ããïŒcm2ïŒãã¿
ãŒã©ã€ãããºããŠãŒãã¹ããã³ãŒãã¬ãŒã·ãšã³ã
ïŒããŒã¹ãããŒã²ã³ãN.J.ïŒè£œã®é»çã䜿çšïŒã
ç §å°ãããæäžå®éšã®ããã«äœ¿çšãããã©ããã¯
ïŒæ©äžçµ¶é£ããã次ãã§åå10æã«å®éšçšè¬å€æ
äžå®éšãéå§ãããã®ããœã³ã®è«æããBiochem.
Pharmacol.ã第26å·»ã第1137é â第1142é
ïŒ1977幎ïŒãã«èšèŒã®è¬å€èª¿è£œæ¹æ³ã«åŸã€ãŠã«ã³ã
ã³ã²ã«ïŒæ°Žå35ïœïŒmlïŒãçšããŠçš®ã ã®çµæã®è¬
å€ã調補ãããã¢ããé žããã³è¬åã¯ãã¹ãŠè ¹è
å ã«æ³šå°ããã è³å ãã€ãã³äžã®ãã«ãšããããªã³ã®åæéã
ãã³ã¿ãŒã³ãªãŒããŒéã次ã®æž¬å®æ¹æ³ã«åŸã€ãŠæž¬
å®ãããããªãã¡ãã®æž¬å®æ¹æ³ã¯ãããããã·ã
ã®æäžåŸã«ããŸãã¯ã©ãããå¯å·ç°å¢äžã«çœ®ãã
åŸã«ãMOPEGâSO4ã®èç©éã枬å®ããããšã
ããªããã®ã§ãã€ããè³ãã¢ãžããŒãäžã®
MOPEGâSO4ããã¢ããªã³äº€æã³ã©ã ããã¢ãŒ
ãã·ã¢ç€ŸïŒãã¹ã«ã¿ãŠãšãŒãN.J.ïŒè£œã®ãâ25
âDEAEâã»ãã¢ããã¯ã¹ãããçšããŠåé¢ããã
ãã®åé¢ã¯ããŒã¯ããã³ããã®æ¹æ³ããBr.J.
Pharmacol.ã第45巻第435é â第441é ïŒ1972
幎ïŒãã«åŸã€ãŠè¡ã€ãããæã ã¯åäžè©Šæã«ãã
ãŠããã·ã³ããã³MOPEGâSO4ã®äž¡è ã枬å®ã§
ããããã«äžèšåé¢æ¹æ³ãæ¹è¯ããŠçšãããåã
ã¢ãžããŒãè©ŠæïŒ0.15MâZnSO4液äžã«å ¥ããã
ã®ïŒã«ã€ããŠãæåã«ããã·ã³ãã¯ãŒã¯ã¹ããã³
ãŠãŒãã³ãã¬ã³ãã®æ¹æ³ããJ.Lab.Med.ã第50å·»
第733é â第736é ïŒ1957幎ïŒãã«åŸã€ãŠå®éããã
次ãã§æ®ãã®ãã¢ãžããŒãã«åœéã®0.15Mâæ°Žé ž
åããªãŠã 液ãæ·»å ããåã³ãã¢ãžãã€ãºããã
ãªã³ã¯ãã³ãã€ã³ã¹ãã«âã¡ã³ã瀟ïŒN.Y.ïŒè£œ
ã®ãããªããã³ããçšããããé å¿åé¢æäœãè¡
ãããããŠäžèšã®ã¡ãŒã¯ããã³ããã®æ¹æ³ã«åŸã€
ãŠMOPEGâSO4ãå®éãããè³ãã¢ãžããŒãå š
äœããã®MOPEGâSO4ããã³ããã·ã³ã®åé¢ã
ååçã¯ãããã70â75ïŒ ããã³85â95ïŒ ã§ãã€
ãã ããã·ã³ãã°ã©ã³ããã¢ã€ã©ã³ãããã€ãªããž
ã«ã«ãã³ã³ãããŒïŒãã³ã°ãã¢ã€ã©ã³ããN.Y.ïŒ
補ã®ãã®ãããã³ããããã·ããã·ã°ããã±ãã«
ã«ãã³ã³ãããŒïŒã»ã³ãã«ã€ã¹ãMOïŒè£œã®ã
ã®ãã¯æ°Žã«é£æº¶æ§ã§ããã®ã§åžNaOH液ã«æº¶è§£
ããåŸãããå溶液ã«å¡©é žãå ããŠç·©è¡äœçšãè¡
ã€ãŠPH7.4ã«ããæ¢ç¥å®¹éã®é£å¡©æ°Žãå ãããã
ãã«ãã€ãŠã泚å°æ¶²ãšããŠé©åœãªåŸ®çŽ°æžæ¿æ¶²ïŒã
ã¢ã€ã³ããµã¹ãã³ãžãšã³ïŒãåŸãããã å¯å·ç°å¢ã«æŽé²ããããšãã«çããã¹ãã¬ã¹ã«
é¢ããå®éšã§ã¯ãè³å ã®ããã·ã³ã®éãå¢å ãã
ãããã«ãããã·ã³ããèªäœã®ä»£ãã«ãäžå±€æº¶ã
æããšãã«ãšã¹ãã«ã®åœ¢ã®ããã·ã³ãè©Šéšåç©ã«
æäžãããå®éšããŒãã®è§£æã¯ãå€æ°äžå 解ææ³
ãŸãã¯äºå 解ææ³ã«åŸã€ãŠè¡ã€ãã ããããã·ãã®æäžã«ããè³å ã®MOPEGâ
SSO4ã®éã123nïœïŒïœïŒåžéå€ã®ã¿ã泚å°ãã
å¯Ÿç §åç©ïŒãã175nïœïŒïœãããããã·ãæäž
åç©ãã«å¢å ããïŒïŒ°ïŒ0.001ïŒç¬¬ïŒè¡šïŒããã·
ã³ã®ã¿ã®æäžã¯è³å ã®MOPEGâSO4ã«å šã圱é¿
ãäžããªãã€ããããã®ã¢ããé žãçšããŠååŠç
ãè¡ã€ãå Žåã«ã¯ãããããã·ãã«ããMOPEG
âSO4ã®éã®å¢å 床ãäžå±€å€§ãããªããããªã
ã¡ã175nïœïŒKgïŒããããã·ãã®åç¬æäžãè¡
ã€ãã©ããã®å ŽåïŒãã203nïœïŒïœã«å¢å ãã
ïŒïŒ°ïŒ0.01ïŒç¬¬ïŒè¡šïŒã
ã¹ïŒäžã®ãããã³ããã³ãã«ãšããããªã³ã®éã
å¶åŸ¡ïŒå¢å€§ãŸãã¯äœäžïŒãåŸãçµæç©ã«é¢ããã
ã®ã§ããã ç¥çµäŒéç©è³ªã§ãããããã³ããã³ãã«ãšãã
ããªã³ããžããããã·ããšãã«ã¢ã©ãã³ïŒããïŒ
ããèªå°ãããç©è³ªã§ããããšã¯æ¢ã«å ¬ç¥ã§ã
ããäžæ¹ãããã¯ãã¢ããé žã§ããããã·ã³ã®é µ
çŽ åŠçããããã·ã«åã«ãããã€ãã³äžã§çæã
ããã®ã§ããããã®ããã»ã¹ã¯ãé µçŽ ã§ãããã
ã·ã³ããããã·ã©ãŒãŒã®è§Šåªäœçšã®ããšã§é²è¡ã
ããããã¯ãé µçŽ ã§ããâã¢ããé žãã«ã«ãã
ã·ã©ãŒãŒïŒAAADïŒã«ããè±ã«ã«ããã·ã«åã
ããŠãããã³ã«ãªãããã«ãšããããªã³ã¯ãé µçŽ
ã§ãããããã³âβâããããã·ã©ãŒãŒããå«ã
ãã€ãã³äžã§ãããã³ããçããããã®äžé£ã®å
å¿ã«ãããŠãåŸé段éã¯ããã·ã³ãããããžã®å€
æ段éã§ããããã®çç±ã®ããã«ãããŒãã³ãœã³
ç ã®åŠããããã³æ¬ ä¹æ§çŸç ã«èµ·å ãã身äœé害
éšãæããæ£è ã«ãããã³æäžãè¡ãããããšã
ãã€ããããããªããéœåã®æªãããšã«ã¯ããã
ãæäžãããšããã¯èº«äœå šäœã®çŽ°èã«åžåãããŠ
ãããã³ã«å€ãããããã«ãã€ãŠããããã®çŽ°è
ã«ãããæ£åžžãªä»£è¬ããã»ã¹ã劚害ããããšãã
äžéœåãªäºæ ãçããã®ã§ãããããã«ããã¯ã
ç¥çµäŒéç©è³ªã§ããã»ãããã³ã®æ£åžžãªäººäœå è
ç©ã劚害ãããã€ãâã¢ããã·ã«ã¡ããªãã³å
åç©ã®è³å ååšéãäœäžãããããããã®äžææ
ã®å¯äœçšã®ããã«æ£è ã«ããããããªã³âãªãçŸ
象ãçãèªããããããšãããããããŠæå Žåã«
ã¯ç²Ÿç¥ç ç城åãèªããããããšããããåŸãã
ã·ããã¹äžã®ãããã³ããã³ãã«ãšããããªã³ã®
éãå¢å ãããäœçšãæããä»çš®è¬å€ã®äŸã«ã¯ã¢
ãã¢ãã³ãªãã·ããŒãŒæå¶å€ïŒããã¯åèšã®ç¥çµ
äŒéç©è³ªã®å解ãé 延ããããã®ã§ããïŒããã³
ïŒæ žåã®ææãã€å€ïŒã¢ã³ãããã¬ãµã³ãïŒãã
ããããããããã®ååç©ã¯æå§çç¶ã䌎ãçŸç
ã®æ²»çå€ãšããŠäœ¿çšãããŠãããããããããŸ
ããã·ããã¹äžã®ãããã³ããã³ãã«ãšããããª
ã³ã®éã®å¢å äœçšã®ä»ã«æ¯èŒçéç¹ç°æ§ã®ååŠç
äœçšãæãããã®ã§ãã€ãŠãããªãã¡çš®ã ã®å¯äœ
çšãæããããšãã°è¡å§äžæäœçšçãæãããã
ãããŠãã®è¡å§äžæã¯ã¢ãã¢ãã³ãªãã·ããŒãŒæ
å¶å€ãæäžããæ£è ãæçš®ã®é£åãé£ã¹ããšãç
ã«èµ·ããã®ã§ããã ã·ããã¹äžã«ãããã³ãŸãã¯ãã«ãšããããªã³
ãéå°éååšãããšãã«èµ·ãä»çš®çŸç ã®äŸã«ã¯æ¬¡
ã®ãã®ããããããïŒç²Ÿç¥ç ïŒãããã³ã®éã極
端ã«å€ãïŒãéåé害çïŒmovement disordersïŒ
ããšãã°ã¿ãŒãžãã»ãžã¹ããã·ã¢çããã³ã®ã¬
ã¹ãããã©ãããŠã¬ããçå矀ïŒãããã³ã®éã
極端ã«å€ãïŒïŒé«è¡å§ããã³äžæŽèïŒäº€æç¥çµã
ã€ãã³ããæŸåºããããã«ãšããããªã³ã®éã極
端ã«å€ãïŒãçŸåšãããã®ç æ°ã®æ²»çã¯äžè¬ã«ã
ãããã³ãŸãã¯ãã«ãšããããªã³ãšãã®åŸæã¬ã»
ãã¿ãŒïŒpostâreceptorsïŒãšã®ã€ã³ã¿ãŒã©ã¯ã·
ãšã³ã劚害ããè¬å€ïŒããšãã°ããšããã¢ãžã³ãŸ
ãã¯ãããããšãã³ïŒãçšããŠè¡ãããŠãããã
ãããªãããããã®è¬å€ã¯ãã¹ãŠãè¥å¹²ã®éç¹ç°
æ§äœçšãè¡šãããã®ã§ãã€ãŠããããã€ãŠãã®æ
çšæã«å¯äœçšãè¡šãããããšãããã ç¥çµäžã®ããã·ã³ã®éãå€ããããšã«ãããã
ãã³ãŸãã¯ãã«ãšããããªã³ã®éãå¢å ãŸãã¯æž
å°ãããè©Šã¿ã以åã«è¡ããããããã®è©Šã¿ã¯æ
åããªãã€ãããªããªãã°è³ããã³çš®ã ã®çµç¹ã®
äžã®ãããã®ååç©ã®éãå€åãããããšã¯è¡ã
ããªãã€ãããã§ãããè³å ã®ããã®æ¿åºŠã¯ãæ
å®ã®å®éšæ¡ä»¶äžã§ã¯ãããã³ããã³ãã«ãšããã
ãªã³ã®åæé床ã«æ¯äŸããŠå€åãããããŠè³å ã®
ããã®æ¿åºŠã¯ãè³å ã®ããã·ã³ã®æ¿åºŠã®å¢å ã«ã
ãå¢å ãããããšãã§ãããã€ãè³å ã®ããã®æ¿
床ã¯ãè³å ã®ããã·ã³ã®æ¿åºŠãäœäžãããããšã
ã§ããïŒã©ãããçšããå®éšïŒããšãæåã«èŠåº
ããç 究è ã¯ã¯ãŒããã³çã§ããïŒããµã€ãšã³ã¹ã
第185巻第183é â第184é ïŒ1974幎ïŒæ12æ¥ïŒãã
è³å ã®ããã·ã³ã®éãå¢å ãããããã®ãåŠçæ¹
æ³ã®ïŒã€ã¯ãããã·ã³ããèªäœãæäžããããšã§
ãã€ããè³å ã®ããã·ã³ã®éãæžå°ãããããã®
åŠçæ¹æ³ã®ïŒã€ã¯ãè¡æŒ¿äžã®ããã·ã³ïŒãã©ãºã
ããã·ã³ïŒã®è³å 移è¡æ§ãšç«¶åããæ§è³ªãæãã
ä»çš®äžæ§ã¢ããé žã®ãã¡ã®ïŒã€ïŒããšãã°ãã€ã·
ã³ïŒãæäžããããšã§ããããã®åŠèª¬ãçºè¡šãã
ã以åã«ã¯ãåèšã®åŸé段éã®åå¿ãé²è¡ããã
é µçŽ ã§ããããã·ã³ããããã·ã©ãŒãŒã¯ããã·ã³
ã«ããé«åºŠé£œåç¶æ ã«ãªã€ãŠããã®ã§ãè³å ã®ã
ãã·ã³ã®éã®å¢å ãŸãã¯æžå°ãããã·ã³ãããã
ãžã®å€æåå¿ã«åœ±é¿ãäžããããšã¯ãªãã§ããã
ãšæãããŠããã®ã§ãããäžæ¹ãäžèšã®ã¯ãŒãã
ã³çã®è«æãŸãã¯å ¶åŸã«çºè¡šãããã®ããœã³åã³
ã¯ãŒããã³è«æããBiochem.Pharmacologyã第
26巻第1137é â第1142é ïŒ1977幎ïŒæå·ïŒãã«ã¯ã
ããèç©éã«é¢ããåèšã®å€åã¯ãè³å ã®ããã
ã³ãŸãã¯ãã«ãšããããªã³ã®éã®å€åã«äŒŽããã®
ã§ããããšã¯å šãé瀺ãããŠããªãããŸãè³å ã®
ããã·ã³ã®éãå€ããããšã«ãããã·ããã¹ãžã®
ãããã³ãŸãã¯ãã«ãšããããªã³ã®æŸåºéã«åœ±é¿
ãäžããããšãã§ããããšãäžèšã®æç®ã«ã¯å šã
é瀺ãããŠããªãã ã·ããã¹äžã«å®éã«ååšãããããã³ããã³ïŒ
ãŸãã¯ãã«ãšããããªã³ã®éãå¢å ãŸãã¯æžå°ã
ããæ段ãéçºããããšã¯ãéåžžã«å¥œãŸããããš
ã§ããããã€ãã³äžã«è²¯èµãããååŠäŒéç©è³ª
ïŒããªãã¡ã·ããã¹äŒéç©è³ªïŒã®ãã¹ãŠã®ååã
çããã·ããã¹ã«å®¹æã«æŸåºã§ãããã®ãšã¯éã
ãªããšããããšãçŸåšå ¬ç¥ã§ãããããã·ããã¹
äžã§ã®è©²ååŠäŒéç©è³ªã®éçå€åã«äŒŽã€ãŠãè³ãŸ
ãã¯ä»ã®çµç¹ã®äžã®ãããã³ãŸãã¯ãã«ãšããã
ãªã³ã®å šéãå€åãããšã¯éããªããåèšã®ã
ããMAOæå¶å€ãããšããã¢ãžã³ããã³ä»ã®è¬
å€ã®æäžæã«äŒŽããããªäžææã®å¯äœçšããªãã
ãã€çååŠçç¹ç°æ§ãæãããããªæ段ãéçºã
ãã®ãæãŸããã®ã§ããããã®ãããªæ段ã¯ãã
ãèªäœãçš®ã ã®ç æ°ã®ããã®æçšãªæ²»çæ段ãšã
ãŠå©çšã§ããã§ãããããããã¯ãçš®ã ã®è¬å€ã®
æ²»çå¹æãäžå±€é«ããããã«ãåèšã®æ段ã¯è©²è¬
å€ãšçµåãããŠå©çšã§ããã§ãããã æ¬çºæã¯ãã·ããã¹äžã®ãããã³ããã³ïŒãŸã
ã¯ãã«ãšããããªã³ã®äžè¶³ãŸãã¯éå°åã䌎ãç
æ°ãæ²»çããããã®çµæç©ãæäŸãããã®ã§ã
ããç¥çµäžã®ããã·ã³ã®éãå¢å ãŸãã¯æžå°ãã
ããããªåŠçã¯ãã·ããã¹äžãžã®ãããã³ãŸãã¯
ãã«ãšããããªã³ã®æŸåºéã®å¢å ãŸãã¯æžå°ãã
ããããã®ã§ãããããããŠåŸè ã®å Žåã®å¢å é
ãŸãã¯æžå°éã¯ãããããåè ã®å Žåã®å¢å éãŸ
ãã¯æžå°éã«å¯Ÿå¿ããå€ã§ããããšãæ¬çºæè ã
æ€åºŠèŠåºãããã®çºèŠã«åºããŠæ¬çºæãå®æãã
ãã®ã§ãããããã·ã³ããã®ãã¬ã«ãŒãµãŒïŒåé§
äœïŒãããšãã«ã¢ã©ãã³ãŸãã¯ä»ã®äžæ§ã¢ããé ž
ã¯åç¬ãŸãã¯æ··åç©ã®åœ¢ã§ããã€ä»ã®è¬å€ãšäžç·
ã«ããŸãã¯äžç·ã«ããã«æäžã§ããããã«ãã€
ãŠãè³å ã®ããã·ã³ïŒããã³ããšãã«ã¢ã©ãã³ïŒ
ã®éãå¢å ãŸãã¯æžå°ãããããšãã§ããããã
ãã®æäžã«ãã€ãŠãã·ããã¹äžã®ãããã³ãã
ã³ïŒãŸãã¯ãã«ãšããããªã³ã®äžè¶³ãŸãã¯éå°ã«
èµ·å ããç æ°ãæ²»çã§ãããåæ§ã«ãåèšæ··åç©
äžã®ããªãããã¢ã³ãŸãã¯ä»ã®ã¢ããé žã®ååšå²
åãçš®ã å€ããããšã«ãããè³å ã®ã»ãããã³ãŸ
ãã¯ä»ã®ç¥çµäŒéç©è³ªã®åæéããã³ã·ããã¹ãž
ã®ãã®æŸåºéã調ç¯ã§ããããããã³æŸåºæ§ãã€
ãã³ãæ¬æ§ç¶æ ã«ãªã€ãŠããå Žåãããªãã¡ãã
ã°ãã°è奮ãããããªå Žåã«ã¯ãããã·ã³ãã
ã³ïŒãŸãã¯ããšãã«ã¢ã©ãã³ã®æäžåŸã«ã·ããã¹
äžã®ãããã³ã®éãå¢å ããã§ãããããã«ãšã
ãããªã³æŸåºæ§ãã€ãã³ãç¹ã«é«æŽ»æ§ã®ãã®ã§ã
ããåŠããšããããšãšã¯ç¡é¢ä¿ã«ãããã·ã³ã®æ
äžã«ããã·ããã¹äžã®ãã«ãšããããªã³ã®éãå¢
å ãããããšãã§ãããããã·ã³å«æéã®äœãäž
æ§ã¢ããé žè£œå€ïŒããªãã¡äžæ§ã¢ããé žçµæç©ïŒ
ãæäžããŠè³å ã®ããã·ã³ã®éãæžå°ãããããš
ã«ãããã·ããã¹äžãžã®ãããã³ããã³ãã«ãšã
ãããªã³ã®æŸåºéãæžå°ãããããšãã§ãããå
æ§ã«ãè³å ã®ããªãããã¢ã³ã®éãæžå°ãããã
ãšã«ãããã»ãããã³ã®æŸåºéãäœäžãããããš
ãã§ãããæå®ã®äžæ§ã¢ããé žæ··åç©ã®äžã®ãã
ã·ã³ã®ååšæ¯çã調æŽããããšã«ããããããã³
ããã³ïŒãŸãã¯ãã«ãšããããªã³ã®æŸåºéãå¢å
ãŸãã¯æžå°ãããããšãã§ãããå°éæäžã®å Žå
ã«ã¯ãããã·ã³ã®ä»£ãã«ããšãã«ã¢ã©ãã³ã䜿çš
ããããšãã§ãããåŸèšã®åŠãããããã³ããã³
ãã«ãšããããªã³ã®æŸåºéã調ç¯ããªããã·ãã
ã¹ãžã®ã»ãããã³ã®æŸåºéã調ç¯ããããã«ãå
èšäžæ§ã¢ããé žæ··åç©äžã«ååšããããªãããã¢
ã³ã®éšåããå©çšããããšãã§ããã æ¬çºæã«åŸãã°ãããã·ã³ããã³ïŒãŸãã¯ããš
ãã«ã¢ã©ãã³ããã³ïŒãŸãã¯ä»ã®äžæ§ã¢ããé žã
åç¬ã§ããŸãã¯ïŒçš®ãŸãã¯ãã以äžã®è¬å€ãšçµå
ãããŠæ£è ã«æäžãããããã«ãã€ãŠãã·ããã¹
ãžã®ãããã³ããã³ïŒãŸãã¯ãã«ãšããããªã³ã®
æŸåºéãå¢å ãŸãã¯æžå°ãããããšãã§ãããå
æã«ãåèšã¢ããé žæ··åç©äžã®ããªãããã¢ã³ã®
ååšæ¯çãçš®ã å€ããããšã«ãããã»ãããã³ã®
æŸåºéã調ç¯ã§ããããããã³ã®æŸåºéãå¢å ã
ããããã«ã¯ãããŒãã³ãœã³ç æ£è ã®å Žåã®ãã
ã«æ£è ã®è³ã®äžã®ãããã³æŸåºæ§ãã€ãã³ã¯æ¯èŒ
çé«æŽ»æ§ã®ãã®ãããªãã¡ã²ãã±ãã«è奮ããã
ã®ã§ããããšãå¿ èŠã§ãããããããªããããã«
ãšããããªã³æŸåºæ§ãã€ãã³ãŸãã¯ã»ãããã³æŸ
åºæ§ãã€ãã³ãç¹ã«é«æŽ»æ§ã®ãã®ã§ãã€ãŠããªã
ãŠãããã®ããšãšã¯ç¡é¢ä¿ã«ãã¢ããé žæ··åç©ã®
䜿çšã«ããã·ããã¹äžãžã®ãã«ãšããããªã³ãŸã
ã¯ã»ãããã³ã®æŸåºéãçš®ã å€ããããšãã§ãã
ã®ã§ãããåæ§ã«ãè³å ã«å ¥ãããã·ã³ãšç«¶åã
åŸããããªã¢ããé žæ··åç©ãæäžããããšã«ã
ãããããã³ãŸãã¯ãã«ãšããããªã³ã®æŸåºéã
æžå°ãããããšãã§ããã ããã§äœ¿çšãããã¢ããé žæ··åç©ã®çµæã¯ãæ²»
çãã¹ãæ£è ã®ç æ°ã®çš®é¡ïŒçç¶ïŒã«å¿ããŠçš®ã
å€ããããšãã§ãããã»ãããã³ã®æŸåºéãå¢å
ãããããšãªããããã³ããã³ïŒãŸãã¯ãã«ãšã
ãããªã³ã®æŸåºéãå¢å ãããå¿ èŠãããå Žåã«
ã¯ãããã·ã³ïŒããã³ïŒãŸãã¯ããšãã«ã¢ã©ã
ã³ïŒããã»ãããã³ã®åé§äœã§ããããªãããã¢
ã³ãå«ãŸãªãä»çš®ã¢ããé žé¡ãšäžç·ã«ããŸãã¯äž
ç·ã«ããã«æäžããããšãã§ãããã®æäžéã¯ïŒ
â200mgïŒKgã§ããåŸãããã®æ²»çæ³ã¯åç¬æ²»ç
æ³ãšããŠããããã¯å¥ã®è¬å€æäžæ²»çæ³ã®è£å©ç
æ³ãšããŠãããšãã°æ¬¡ã®ç æ°ã«æå¹ã§ããïŒããŒ
ãã³ãœã³ç ïŒæçš®ã®æå§çç¹ã«é«è¡å§ïŒæ«æ¢¢äº€æ
ç¥çµç³»ã®æ©èœæå·ã«ããäœè¡å§ïŒãªã«ãœã¹ã¿ãã
ã¯äœè¡å§ïŒãæå Žåã«ã¯ãããã·ã³ã®ä»£çšç©ãšã
ãŠããšãã«ã¢ã©ãã³ã䜿çšã§ããããªããªãã°ã
ã®ã¢ããé žã¯èèå ã§ããã·ã³ã«å€æããããã
ãŠè¡æ¶²æµã®äžã«æŸåºãããè³ã®äžã«å ¥ãããã§ã
ããããããªãããè¡æŒ¿äžã®ããšãã«ã¢ã©ãã³ã®
æ¿åºŠã¯ãããã·ã³ã®æ¿åºŠã®çŽïŒåãããäœãå€ã§
ããã¹ãã§ããããªããªãã°ããã®ãããªé«ãæ¿
床ã§ã¯è³å 移è¡ã«é¢ããŠããšãã«ã¢ã©ãã³ã¯ãã
ã·ã³ãšç«¶åããããã·ã³ããããã·ã©ãŒãŒé µçŽ ã®
äœçšã劚害ããããšãããåŸãããã§ããã è³å ã®ã»ãããã³ã®éããã®ãŸãŸç¶æããããŸ
ãã¯å¢å ãããªãããããã³ãŸãã¯ãã«ãšããã
ãªã³ã®æŸåºéãå¢å ãããå¿ èŠãããå Žåã«ã¯ã
ããã·ã³ããã³ïŒãŸãã¯ããšãã«ã¢ã©ãã³ããã³
ä»çš®äžæ§ã¢ããé žã®ä»ã«ããã«ããªãããã¢ã³ã
ãå«ãçµæç©ã䜿çšããã®ãããããã®ãããªçµ
æç©ïŒãŸãã¯äžèšã¢ããé žã®çµåãïŒã¯ãæçš®ã®
æãã€ç¶æ ãŸãã¯ç¡ç é害ã®æ²»çå€ãšããŠç¹ã«æ
çšã§ãããäžèšã«äŸç€ºããçµæç©ãå«æãåŸãã¢
ããé žä»¥å€ã®äžæ§ã¢ããé žã®äŸã«ã¯åæç¶ã¢ãã
é žïŒãã€ã·ã³ãã€ãœãã€ã·ã³ãããªã³ïŒããã³ã¡
ããªãã³ãã¹ã¬ãªãã³ããã¹ããžã³ããããã
ãããããã®ã¢ããé žã¯åéäœãŸãã¯å€©ç¶ãŸãã¯
åæéåäœïŒããšãã°ããããïŒã®åœ¢ã§æäžã§ã
ãã以äžã®èšèŒã§ã¯ãããšãã«ã¢ã©ãã³ãããªã
ããã¢ã³ããã³ããã·ã³ãæçšã¢ããé žããšç§°ã
ãããšã«ããã ããšãã°ç²Ÿç¥ç ãéåé害çïŒããšãã°ã¿ãŒãž
ãã»ãžã¹ããã·ã¢çãŸãã¯ã®ã¬ã¹ãããã©ãããŠ
ã¬ããçå矀ïŒçã®ç æ°ãããªãã¡ãããããŒãž
ãã¯ïŒdopaminergicïŒãã€ãã³ãå€åè¶ æŽ»æ§ç¶
æ ã«ãªã€ãŠããç æ°ã§ã¯ãã·ããã¹äžã®ãããã³
ã®éãæžå°ãããå¿ èŠããããããã®ãããªå Žå
ã«ã¯ãããã·ã³ãŸãã¯ããšãã«ã¢ã©ãã³ãå šãå«
ãŸãªãããŸãã¯æ¯èŒçå°éããå«ãŸãªãäžæ§ã¢ã
ãé žæ··åç©ãæäžããããããšåæ§ãªæ··åç©ã¯ã
ã·ããã¹äžã®ãã«ãšããããªã³ã®éãæžå°ããã
ããã«äœ¿çšã§ãããã€ãŸããã·ããã¹ã®ããªãã
ãã¢ã³å«æéã«å¿ããŠã·ããã¹äžã®ã»ãããã³ã®
éãå¢å ãŸãã¯æžå°ãããããã«ã䜿çšã§ããã ããã·ã³ãããšãã«ã¢ã©ãã³ããã³ããªããã
ã¢ã³ã®è¡æŒ¿äžæ¿åºŠãšãä»ã®äžæ§ã¢ããé žå šäœã®è¡
挿äžæ¿åºŠãšã®æ¯çã¯é£ç©ã®çµæã«å·Šå³ããããã
æ£åžžæã®ãã®æ¯ã®å€ã¯äžè¬ã«ããããçŽ0.08â
0.12ãçŽ0.07â0.12ããã³çŽ0.06â0.14ã§ãããæ
çš®ã®ç æ°ã®å Žåã«ã¯ãããšãã°ãæç¡ãæãè硬
å€ãç³å°¿ç ãã€ã³ã·ãŠãªã³éå°ç
ïŒhyperinsulinismïŒãç°åçç¶ïŒé£¢é€ãæªæ¶²è³ªã
åºãã€ãã¬ã³ïŒãã²ã©ãç«å·ãŸãã¯å€å·çã®ç æ°
ã®å Žåã«ã¯ãäžèšã®æ¯ã®å€ãç°åžžå€ã«ãªããè³ã«
ããããããã³ããã«ãšããããªã³ããã³ã»ãã
ãã³ã®æŸåºéã®å€åãããããããã®ãããªå Žå
ã«äœ¿çšãããã¢ããé žçµæç©ã¯ãåèšã®è¡æŒ¿äžæ¿
床ã®å€ãæ£åžžå€ã«æ»ãã®ã«é©ããçµæãæããã
ã®ã§ããã¹ãã§ãããäžèšã«äŸç€ºãããããªäž»ãš
ããŠç²Ÿç¥ç¥çµççç¶ã䌎ãç æ°ã®å Žåã«ã¯ããã®
ã¢ããé žçæ³ã®ç®æšã¯ãã·ããã¹äžãžã®ãããã³
ãŸãã¯ãã«ãšããããªã³ïŒãŸãã¯ã»ãããã³ïŒã®
æŸåºéãå¢å ãŸãã¯æžå°ãããããã«ãåèšã®æ¯
ã®å€ïŒããã¯çœ¹ç æã«ã¯åèšã®æ£åžžç¯å²å ã®å€ã
ããé«ãããŸãã¯äœãå€ã«ãªã€ãŠããïŒãäœãã
ããŸãã¯é«ããããšã§ããã ããã·ã³ãããšãã«ã¢ã©ãã³ããã³ä»ã®äžæ§ã¢
ããé žã¯ãéé¢ã¢ããé žããã®ãšã¹ãã«ãå¡©ã倩
ç¶ãŸãã¯åæéåäœã®åœ¢ã§æäžã§ãããããã¯é£
åã®æ§ææåã®åœ¢ã§æäžã§ããããã®æäžã¯çµå£
æäžãŸãã¯éçµå£æäžïŒããšãã°éèå 泚å°ïŒã®
圢ã§è¡ãããšãã§ããã æ¬çºæãäžå±€å ·äœçã«äŸç€ºããããã«ã次ã«å®
æœäŸã瀺ããããããªããæ¬çºæã®ç¯å²ã¯æ±ºããŠ
ãããã®å®æœäŸã«èšèŒã®ç¯å²å ã®ã¿éå®ãããã
ã®ã§ã¯ãªãã äŸ ãã®å®æœäŸã¯ãè³å ã§ãã«ãšããããªã³ãè³å
ã®ããã·ã³ã®éãå¢å ãããããšã«ããåæã§ã
ãããšãäŸç€ºãããã®ã§ããã ãã®å®æœäŸäžã®å®éšããŒã¿ãŒã«ç€ºãããŠããã
ãã«ãè³å ã®ãã«ãšããããªã³ã®äž»ä»£è¬ç£ç©ã§ã
ãïŒâã¡ããã·âïŒâããããã·âããšãã«ãšã
ã¬ã³ã°ãªã³ãŒã«âãµã«ããšãŒãïŒMOPEGâ
SO4ïŒãã©ããã®è³å ã«èç©ãããšãã®èç©é床
ã¯ãè³å ã®ããã·ã³ã®éã®é¢æ°ã®åœ¢ã§çš®ã å€åã
ããã®ã§ããããã®ããšããæãããªããã«è³å
ã®ããã·ã³ã®éã¯ãè³å ã®ãã«ãšããããªã³ã®å
æéã®ã¿ãªããããã®ãã«ãšããããªã³ã®ã¿ãŒã³
ãªãŒããŒéããã³æŸåºéã«ã圱é¿ãäžãããã®ã§
ããã äœé150ïœã®ãªã¹ã®ã¹ãã©ã°ãŒâããŒã¬ã€ã©ã
ãããã€ãŒã«ã¹ããªããŒãããªãŒãžã³ã°ãã©ãã©
ããªãŒãºïŒãŠã€ã«ãã³ã°ãã³ãMAïŒããäŸçµŠã
ãããã®ãããã€ãããããã«å ¥ããŠé£Œè²ãã
ïŒïŒããåœãïŒâïŒå¹ïŒããããŠé£²ææ°Žããã³26ïŒ
èçœè³ªé£ŒæïŒãã€ãŒã«ã¹ããªããŒãã©ããâããŠ
ã¹âãã ã¹ã¿ãŒãã¡ã€ã³ããã³ã¹ãããªãŒããŠã©
ãŒ24RFïŒãèªç±ã«äžãããæ¯æ¥ååïŒæããå
åŸïŒæãŸã§å ç·ã300ãã€ã¯ãã¯ããïŒcm2ïŒãã¿
ãŒã©ã€ãããºããŠãŒãã¹ããã³ãŒãã¬ãŒã·ãšã³ã
ïŒããŒã¹ãããŒã²ã³ãN.J.ïŒè£œã®é»çã䜿çšïŒã
ç §å°ãããæäžå®éšã®ããã«äœ¿çšãããã©ããã¯
ïŒæ©äžçµ¶é£ããã次ãã§åå10æã«å®éšçšè¬å€æ
äžå®éšãéå§ãããã®ããœã³ã®è«æããBiochem.
Pharmacol.ã第26å·»ã第1137é â第1142é
ïŒ1977幎ïŒãã«èšèŒã®è¬å€èª¿è£œæ¹æ³ã«åŸã€ãŠã«ã³ã
ã³ã²ã«ïŒæ°Žå35ïœïŒmlïŒãçšããŠçš®ã ã®çµæã®è¬
å€ã調補ãããã¢ããé žããã³è¬åã¯ãã¹ãŠè ¹è
å ã«æ³šå°ããã è³å ãã€ãã³äžã®ãã«ãšããããªã³ã®åæéã
ãã³ã¿ãŒã³ãªãŒããŒéã次ã®æž¬å®æ¹æ³ã«åŸã€ãŠæž¬
å®ãããããªãã¡ãã®æž¬å®æ¹æ³ã¯ãããããã·ã
ã®æäžåŸã«ããŸãã¯ã©ãããå¯å·ç°å¢äžã«çœ®ãã
åŸã«ãMOPEGâSO4ã®èç©éã枬å®ããããšã
ããªããã®ã§ãã€ããè³ãã¢ãžããŒãäžã®
MOPEGâSO4ããã¢ããªã³äº€æã³ã©ã ããã¢ãŒ
ãã·ã¢ç€ŸïŒãã¹ã«ã¿ãŠãšãŒãN.J.ïŒè£œã®ãâ25
âDEAEâã»ãã¢ããã¯ã¹ãããçšããŠåé¢ããã
ãã®åé¢ã¯ããŒã¯ããã³ããã®æ¹æ³ããBr.J.
Pharmacol.ã第45巻第435é â第441é ïŒ1972
幎ïŒãã«åŸã€ãŠè¡ã€ãããæã ã¯åäžè©Šæã«ãã
ãŠããã·ã³ããã³MOPEGâSO4ã®äž¡è ã枬å®ã§
ããããã«äžèšåé¢æ¹æ³ãæ¹è¯ããŠçšãããåã
ã¢ãžããŒãè©ŠæïŒ0.15MâZnSO4液äžã«å ¥ããã
ã®ïŒã«ã€ããŠãæåã«ããã·ã³ãã¯ãŒã¯ã¹ããã³
ãŠãŒãã³ãã¬ã³ãã®æ¹æ³ããJ.Lab.Med.ã第50å·»
第733é â第736é ïŒ1957幎ïŒãã«åŸã€ãŠå®éããã
次ãã§æ®ãã®ãã¢ãžããŒãã«åœéã®0.15Mâæ°Žé ž
åããªãŠã 液ãæ·»å ããåã³ãã¢ãžãã€ãºããã
ãªã³ã¯ãã³ãã€ã³ã¹ãã«âã¡ã³ã瀟ïŒN.Y.ïŒè£œ
ã®ãããªããã³ããçšããããé å¿åé¢æäœãè¡
ãããããŠäžèšã®ã¡ãŒã¯ããã³ããã®æ¹æ³ã«åŸã€
ãŠMOPEGâSO4ãå®éãããè³ãã¢ãžããŒãå š
äœããã®MOPEGâSO4ããã³ããã·ã³ã®åé¢ã
ååçã¯ãããã70â75ïŒ ããã³85â95ïŒ ã§ãã€
ãã ããã·ã³ãã°ã©ã³ããã¢ã€ã©ã³ãããã€ãªããž
ã«ã«ãã³ã³ãããŒïŒãã³ã°ãã¢ã€ã©ã³ããN.Y.ïŒ
補ã®ãã®ãããã³ããããã·ããã·ã°ããã±ãã«
ã«ãã³ã³ãããŒïŒã»ã³ãã«ã€ã¹ãMOïŒè£œã®ã
ã®ãã¯æ°Žã«é£æº¶æ§ã§ããã®ã§åžNaOH液ã«æº¶è§£
ããåŸãããå溶液ã«å¡©é žãå ããŠç·©è¡äœçšãè¡
ã€ãŠPH7.4ã«ããæ¢ç¥å®¹éã®é£å¡©æ°Žãå ãããã
ãã«ãã€ãŠã泚å°æ¶²ãšããŠé©åœãªåŸ®çŽ°æžæ¿æ¶²ïŒã
ã¢ã€ã³ããµã¹ãã³ãžãšã³ïŒãåŸãããã å¯å·ç°å¢ã«æŽé²ããããšãã«çããã¹ãã¬ã¹ã«
é¢ããå®éšã§ã¯ãè³å ã®ããã·ã³ã®éãå¢å ãã
ãããã«ãããã·ã³ããèªäœã®ä»£ãã«ãäžå±€æº¶ã
æããšãã«ãšã¹ãã«ã®åœ¢ã®ããã·ã³ãè©Šéšåç©ã«
æäžãããå®éšããŒãã®è§£æã¯ãå€æ°äžå 解ææ³
ãŸãã¯äºå 解ææ³ã«åŸã€ãŠè¡ã€ãã ããããã·ãã®æäžã«ããè³å ã®MOPEGâ
SSO4ã®éã123nïœïŒïœïŒåžéå€ã®ã¿ã泚å°ãã
å¯Ÿç §åç©ïŒãã175nïœïŒïœãããããã·ãæäž
åç©ãã«å¢å ããïŒïŒ°ïŒ0.001ïŒç¬¬ïŒè¡šïŒããã·
ã³ã®ã¿ã®æäžã¯è³å ã®MOPEGâSO4ã«å šã圱é¿
ãäžããªãã€ããããã®ã¢ããé žãçšããŠååŠç
ãè¡ã€ãå Žåã«ã¯ãããããã·ãã«ããMOPEG
âSO4ã®éã®å¢å 床ãäžå±€å€§ãããªããããªã
ã¡ã175nïœïŒKgïŒããããã·ãã®åç¬æäžãè¡
ã€ãã©ããã®å ŽåïŒãã203nïœïŒïœã«å¢å ãã
ïŒïŒ°ïŒ0.01ïŒç¬¬ïŒè¡šïŒã
ãè¡šã
泚ïŒãããã®ïŒã€ã®å®éšã®åã
ã«ãããŠãïŒâ
ïŒå¹ã®ã©ãããïŒã°ã«ãŒãã«ããŠãåã°ã«ãŒãã®
ã©ããã«ãæå®ã®æäžéã®ããã·ã³ïŒè³å ã®ãã
ã®åæãä¿é²ããããšãç¥ãããŠããè¬å€ïŒ100
mgïŒKgãi.p.ïŒãããã¯ãã®åžéå€ã®ã¿ã泚å°ãã
ãããŠ30ååŸã«ããããã·ãïŒ400mgïŒKgãi.p.ïŒ
ãŸãã¯ãã®åžéå€ã®ã¿ã泚å°ããããã®ç¬¬ïŒåç®
ã®æ³šå°ãè¡ã€ãŠãã60ååŸã«è©Šéšåç©ã殺ããã
ã®è³å šäœã«ã€ããŠåæãè¡ã€ãŠããã·ã³ããã³
MOPEGâSO4ã®éã枬å®ãããããã·ã³ã®æäž
ã«ããè³å ã®ããã·ã³ã®éã¯èããå¢å ããïŒïŒ°
±0.001ïŒãäžæ¹ãããããã·ãã¯è³å ã®ããã·ã³
ãå€æ§ãããã®ã§ããªãããŸããå€æ¥ããã·ã³ãž
ã®ãã®ã¬ã¹ãã³ã¹ãå€æ¹ããããã®ã§ããªãã€
ããããããã·ãã¯è³å ã®MOPEGâSO4ã®éã
èããå¢å ããïŒïŒ°Â±0.001ïŒããããŠããã·ã³ã®
ååŠçã«ããããã®ã¬ã¹ãã³ã¹ãèããå¢å€§ãã
ïŒïŒ°Â±0.01ïŒããããã®å®éšããŒã¿ãŒã¯ãå€æ°äºå
解ææ³ã«ãã解æããããããã®å€ã¯ã±SENã
ã§è¡šããããã ã©ãããå¯å·ç°å¢ïŒïŒâïŒäžã«é£Œè²ããå Žåã«
ã¯ãã«ãšããããªã³ã®ã¿ãŒã³ãªãŒããŒéãå¢å
ãããããŠããã«ãã€ãŠãè³å ã®ãã€ãã³äžã®ã
ã«ãšããããªã³èªäœããã³ãã®ä»£è¬ç£ç©
ïŒMOPEGâSO4ïŒã®äž¡è ã®çæãä¿é²ãããã
ã©ãããå¯å·ç°å¢äžã«é£Œè²ããŠæ¬¡ã®ããšã調ã¹
ããããªãã¡ãè³å ã®ããã·ã³ã®éãå€ããåŠç
ã¯ãå¯å·ã¹ãã¬ã¹ãåããã©ããïŒããããã·ã
ãæäžããªãã€ãã©ããïŒã®è³å ã®MOPEGâ
SO4èç©é床ã«åœ±é¿ãäžãããã®ã§ãããã©ãã
ã調ã¹ãïŒç¬¬ïŒå³ïŒã å¯å·ç°å¢äžã«ïŒæé眮ããšè³å ã®MOPEGâ
SO4ã®éãçŽ40ïŒ å¢å ããïŒããªãã¡ãã®éã¯
80nïœïŒïœãã114nïœïŒïœã«å¢å ããïŒïŒ°ïŒ
0.01ïŒãã¢ããé žãŸãã¯é£å¡©æ°Žã®ãããããæäž
ããè©Šéšåç©ã§ã¯ãè³å ã®ããã·ã³ã®éã¯å€§äœå
ãã§ããããã€ããã¯MOPEGâSO4ã®éã«å¯æ¥
ã«é¢é£ãããã®ã§ãã€ãïŒïœïŒ77ïŒïŒ°ïŒ0.05ïŒç¬¬
ïŒå³ïŒãããã·ã³æäžã«ããååŠçã«ããè³å ã®
ããã·ã³ã®éãçŽ80ïŒ å¢å ããããªãã¡ã13.3ÎŒ
ïœïŒïœïŒé£å¡©æ°Žã泚å°ããåç©ã®å ŽåïŒãã
24.6ÎŒïœïŒïœã«å¢å ããïŒïŒ°ïŒ0.01ããMOPEGâ
SO4ã®éã¯çŽ70ïŒ å¢å ããïŒããªãã¡ã114nïœïŒ
ïœãã193nïœïŒïœã«å¢å ããïŒïŒ°ïŒ0.01ïŒããã®
å®éšã§ã¯ããªã³ã®æäžã«ããååŠçãè¡ã€ããã
ãã®å Žåã«ã¯è³å ã®ããã·ã³ãŸãã¯MOPEGâ
SO4ã®éã¯å®è³ªçã«ç¡å€åã§ãã€ãïŒããªãã¡ã
ã®ïŒã€ã®éã¯ãããã14.3ÎŒïœïŒïœããã³117n
ïœïŒïœã§ãã€ãïŒãããããªãããä»ã®ã°ã«ãŒã
ã«å¯Ÿããå®éšã®çµæïŒç¬¬ïŒå³ïŒããæãããªãã
ã«ãè³å ã®ããã·ã³ããã³MOPEGâSO4ã®é
ã¯ãè©Šéšåç©èªäœãšãå¯æ¥ã«é¢é£ãããã®ã§ãã€
ãã 第ïŒå³èšèŒã®çžé¢é¢ä¿ã¯æ¬¡ã®å®éšã§åŸãããã
ã®ã§ãã€ããè€æ°ã®ã°ã«ãŒãã®ã©ããã®åã ã®è ¹
èå ã«ããªã³ïŒ200mgïŒKgïŒããŸãã¯ãè³å åžåæ§
ã«é¢ããŠããã·ã³ãšç«¶åããæ§è³ªãæããã¢ãã
é ž(8)ããŸãã¯ããã·ã³ïŒãšãã«ãšã¹ãã«ã®åœ¢ã®ã
ãã·ã³125mgïŒKgïŒããŸãã¯é£å¡©æ°Žã泚å°ããã30
ååŸã«ãã®ã©ãããã·ã³ã°ã«ã±ãŒãžïŒããïŒã«å ¥
ããŠå¯å·ç°å¢ïŒïŒâïŒäžã«çœ®ãããïŒæéåŸã«è©Š
éšåç©ãå šéšæ®ºãããã®è¡æ¶²å šéšã«ã€ããŠåæã
è¡ã€ãŠããã·ã³ããã³MOPEGâSO4ã®éã枬å®
ãããå¯Ÿç §åç©ã«ã¯é£å¡©ã泚å°ããã·ã³ã°ã«ã±ãŒ
ãžã«å ¥ããŠå®€æž©ïŒ22âïŒã«ãããŠ90åéä¿ã€ãã
ã°ã©ãäžã®åç¹ã¯ïŒã€ã®è³ã®äžã«ååšããããã·
ã³ããã³MOPEGâSO4ã®éãè¡šããããããã®
ããŒã¿ã¯ãè¥å¹²ã®å®éšçµæãéèšããŠç®åºããã
ãã®ã§ãã€ãã宀枩ã«ãããŠé£Œè²ãããè©Šéšåç©
ã®è³å ã®ããã·ã³ããã³MOPEGâSO4ã®éã¯ã
ããã14.6ÎŒïœããã³80nïœïŒïœã§ãã€ãã第ïŒå³
ã®ã°ã©ãã«ãããŠãåèšå·ã¯æ¬¡ã®æå³ãæããïŒ
é»äžžââããªã³ã§ååŠçãããåç©ã«ããã枬å®
å€ïŒçœäžžââé£å¡©æ°Žã§ååŠçãããåç©ã«ããã
枬å®å€ïŒçœãåè§ââããã·ã³ã§ååŠçãããå
ç©ã«ããã枬å®å€ã è³å ã®ããã·ã³ã®éã®ççåŠçãã©ããããŸ
ãããã«ãšããããªã³ã®åæéããã³ã¿ãŒã³ãªãŒ
ããŒéïŒããã¯ãMOPEGâSO4ã®éã®æž¬å®ã«ã
ã枬å®ã§ããïŒã«åœ±é¿ãäžãããã®ã§ãããã©ã
ããã¿ãããã«ã次ã®å®éšãè¡ã€ããããªãã¡ã
å¯å·ç°å¢äžã«çœ®ããè©Šéšåç©ã«ãããäžèšã®ä»£è¬
ç£ç©ã®èç©éã調ã¹ãæäœããããã·ã³ã®éãé«
ãããšæãããåçŽé£ŒæïŒsingle mealïŒãé£ã¹
ãããåŸã«è¡ã€ãã ïŒæ©äžçµ¶é£ãããè©Šéšåç©ã«ç¡èçœé£ŒæïŒã«ãŒ
ã€ã³ïŒïŒ ïŒãŸãã¯40ïŒ ã«ãŒã€ã³é£Œæãåå10æã
ãåå11æãŸã§ã®æéã«ããã€ãŠäžãã次ãã§è©Š
éšåç©ãå¯å·ç°å¢ïŒïŒâïŒäžã«ïŒæéä¿ã¡ã次ã
ã§ããã殺ãããã®è³ãåæããŠããã·ã³ããã³
MOPEGâSO4ã®éã枬å®ããã絶é£ãããå¯Ÿç §
åç©ã¯ããã®ïŒæéã«ããã€ãŠå®€æž©ïŒ22âïŒã«ã
ããŠä¿ã€ãã 絶é£ãããã©ãããå¯å·ç°å¢äžã«ä¿ã€ããšã«ã
ãããã®è³å ã®MOPEGâSO4ã®èç©ãä¿é²ã§
ãããã®éã¯123nïœïŒ22âã«ãããŠä¿ããã絶
é£å¯Ÿç §åç©ïŒãã163nïœã«å¢å ããïŒïŒ°ïŒ0.05ãã
ãã®åŠçã¯è³å ã®ããã·ã³ã®éã«ã¯å šã圱é¿ãäž
ããªãã€ãïŒ10.1ÎŒïœïŒïœå¯Ÿ10.5ÎŒïœïŒïœïŒãå¯å·
ç°å¢äžã«çœ®ãããåç©ã®ãã¡ã§ãïŒïŒ ã«ãŒã€ã³é£Œ
æãŸãã¯40ïŒ ã«ãŒã€ã³é£Œæãæäžããåç©ã§ã¯ã
è³å ã®MOPEGâSO4ã®èç©éã40â50ïŒ å¢å ã
ãïŒç¬¬ïŒè¡šïŒïŒ°ïŒ0.01ïŒãïŒïŒ ã«ãŒã€ã³é£Œæãæ
äžããåç©ã§ã¯è³å ã®ããã·ã³ã®éãçŽ40ïŒ å¢å
ãïŒïŒ°ïŒ0.01ïŒãäžæ¹ã40ïŒ ã«ãŒã€ã³é£Œæãé£ã¹
ãåç©ã§ã¯è³å ã®ããã·ã³ã®éã77ïŒ å¢å ãã
ïŒïŒ°ïŒ0.01ïŒã ç¡èçœè³ªé£Œæã®æäžãè³å ã®ããã·ã³ã®éã®å¢
å ããããããªãã€ãå Žåã«ã¯ãè³å ã®MOPEG
âSO4ã®éããŸãå¢å ããªãã€ãïŒç¬¬ïŒè¡šïŒãã
ã®å®éšã«ãããŠãèçœè³ªãæäžããåç©ã§ã¯è³å
ã®ããã·ã³ã®éãçŽ50ïŒ å¢å ãïŒããªãã¡ã
13.4ÎŒïœïŒïœãã19.5ÎŒïœïŒïœã«å¢å ããïŒïŒ°ïŒ
0.01ïŒããã€ããã«äžŠè¡ããŠè³å ã®MOPEGâSO4
ã®éãå¢å ããã ãããã®å®éšããŒã¿ãŒããæãããªããã«ãã
ãããã·ãã§ååŠçããããŸãã¯å¯å·ç°å¢äžã«çœ®
ããã©ããã§ã¯ãè³å ã®ããã·ã³ã®éãå¢å ãã
ãåŠçãè¡ãããšã«ãããè³å ã®ãã«ãšããããª
ã³ã®ä»£è¬ç£ç©ã§ããMOPEGâSO4ã®èç©éãå¢
å ãããããšãã§ããã®ã§ããããã®ãããªåŠç
ã¯è¬çåŠçåŠçïŒããªãã¡ãããã·ã³ã®è ¹èå 泚
å°ïŒãŸãã¯ççåŠçåŠçïŒããªãã¡ãé«èçœè³ªé£Œ
æã®æäžïŒã§ãã€ãŠããããããã®åŠçã¯ãè³å
ã®ããã·ã³æ¿åºŠã«é¢ããŠããã®åºè³ªïŒãµãã¹ãã¬
ãŒãïŒã®ããã®ããã·ã³ããããã·ã©ãŒãŒã®é«Km
æ§ã«å¹æµããå¹æãäžãããã®ã§ããããã®é µçŽ
ã¯ãåºè³ªã«ã€ããŠå¶éæ¡ä»¶ããããšããæ¬ ç¹ãæ
ããããªããªãã°ããã®é µçŽ ã掻æ§åããããšã
ã«ããã®æŽ»æ§ãããã®ã³ãã¢ã¯ã¿ãŒã«å¯Ÿãã芪å
æ§ãéžæçã«é«ããããã§ããã MOPEGâSO4ã¯ã©ããã®è³å ã«ããããã«ãš
ããããªã³ã®äž»ä»£è¬ç£ç©ã§ãã€ãŠãããã¯ããã
ããã·ãã«ææãªã¡ã«ããºã ã«ããè³å€ã«éã³åº
ããããããããã·ãã®æäžåŸã«ã¯MOPEGâ
SO4ã¯ã©ããã®è³å ã«ãå°ããšã60åéã«ããã€
ãŠãæéã«çŽç·çã«æ¯äŸããéçå²åã§èç©ã
ãããã®æéã®éã¯è³å ã®ãã«ãšããããªã³ã®é
ã¯äžå€ç¶æ ã®ãŸãŸä¿ãããŠãããããMOPEGâ
SO4ã®èç©çïŒèç©éïŒã¯ããã«ãšããããªã³ã®
åæçã瀺ãæçšãªææšãšããŠåœ¹ç«ã€ãã®ã§ã
ãããã®èç©çã¯ãã¹ãã¬ã¹ãäžããã«ãããã
ã·ãåŠçãè¡ã€ãã©ããã®å Žåã«ã¯ãå¯å·ç°å¢äž
ã«çœ®ãããã©ããã®å Žåãããæããã«äœãã€ã
ïŒç¬¬ïŒè¡šããã³ç¬¬ïŒè¡šïŒãããããªãããã©ããã
ãã®ïŒã€ã®ç°å¢ã®ãã¡ã®ãããã®ç°å¢ã®ããšã§çœ®
ããå Žåã§ããäžèšã®èç©çã¯è³å ã®ããã·ã³ã®
éã«å·Šå³ãããå€ã§ããã
ïŒå¹ã®ã©ãããïŒã°ã«ãŒãã«ããŠãåã°ã«ãŒãã®
ã©ããã«ãæå®ã®æäžéã®ããã·ã³ïŒè³å ã®ãã
ã®åæãä¿é²ããããšãç¥ãããŠããè¬å€ïŒ100
mgïŒKgãi.p.ïŒãããã¯ãã®åžéå€ã®ã¿ã泚å°ãã
ãããŠ30ååŸã«ããããã·ãïŒ400mgïŒKgãi.p.ïŒ
ãŸãã¯ãã®åžéå€ã®ã¿ã泚å°ããããã®ç¬¬ïŒåç®
ã®æ³šå°ãè¡ã€ãŠãã60ååŸã«è©Šéšåç©ã殺ããã
ã®è³å šäœã«ã€ããŠåæãè¡ã€ãŠããã·ã³ããã³
MOPEGâSO4ã®éã枬å®ãããããã·ã³ã®æäž
ã«ããè³å ã®ããã·ã³ã®éã¯èããå¢å ããïŒïŒ°
±0.001ïŒãäžæ¹ãããããã·ãã¯è³å ã®ããã·ã³
ãå€æ§ãããã®ã§ããªãããŸããå€æ¥ããã·ã³ãž
ã®ãã®ã¬ã¹ãã³ã¹ãå€æ¹ããããã®ã§ããªãã€
ããããããã·ãã¯è³å ã®MOPEGâSO4ã®éã
èããå¢å ããïŒïŒ°Â±0.001ïŒããããŠããã·ã³ã®
ååŠçã«ããããã®ã¬ã¹ãã³ã¹ãèããå¢å€§ãã
ïŒïŒ°Â±0.01ïŒããããã®å®éšããŒã¿ãŒã¯ãå€æ°äºå
解ææ³ã«ãã解æããããããã®å€ã¯ã±SENã
ã§è¡šããããã ã©ãããå¯å·ç°å¢ïŒïŒâïŒäžã«é£Œè²ããå Žåã«
ã¯ãã«ãšããããªã³ã®ã¿ãŒã³ãªãŒããŒéãå¢å
ãããããŠããã«ãã€ãŠãè³å ã®ãã€ãã³äžã®ã
ã«ãšããããªã³èªäœããã³ãã®ä»£è¬ç£ç©
ïŒMOPEGâSO4ïŒã®äž¡è ã®çæãä¿é²ãããã
ã©ãããå¯å·ç°å¢äžã«é£Œè²ããŠæ¬¡ã®ããšã調ã¹
ããããªãã¡ãè³å ã®ããã·ã³ã®éãå€ããåŠç
ã¯ãå¯å·ã¹ãã¬ã¹ãåããã©ããïŒããããã·ã
ãæäžããªãã€ãã©ããïŒã®è³å ã®MOPEGâ
SO4èç©é床ã«åœ±é¿ãäžãããã®ã§ãããã©ãã
ã調ã¹ãïŒç¬¬ïŒå³ïŒã å¯å·ç°å¢äžã«ïŒæé眮ããšè³å ã®MOPEGâ
SO4ã®éãçŽ40ïŒ å¢å ããïŒããªãã¡ãã®éã¯
80nïœïŒïœãã114nïœïŒïœã«å¢å ããïŒïŒ°ïŒ
0.01ïŒãã¢ããé žãŸãã¯é£å¡©æ°Žã®ãããããæäž
ããè©Šéšåç©ã§ã¯ãè³å ã®ããã·ã³ã®éã¯å€§äœå
ãã§ããããã€ããã¯MOPEGâSO4ã®éã«å¯æ¥
ã«é¢é£ãããã®ã§ãã€ãïŒïœïŒ77ïŒïŒ°ïŒ0.05ïŒç¬¬
ïŒå³ïŒãããã·ã³æäžã«ããååŠçã«ããè³å ã®
ããã·ã³ã®éãçŽ80ïŒ å¢å ããããªãã¡ã13.3ÎŒ
ïœïŒïœïŒé£å¡©æ°Žã泚å°ããåç©ã®å ŽåïŒãã
24.6ÎŒïœïŒïœã«å¢å ããïŒïŒ°ïŒ0.01ããMOPEGâ
SO4ã®éã¯çŽ70ïŒ å¢å ããïŒããªãã¡ã114nïœïŒ
ïœãã193nïœïŒïœã«å¢å ããïŒïŒ°ïŒ0.01ïŒããã®
å®éšã§ã¯ããªã³ã®æäžã«ããååŠçãè¡ã€ããã
ãã®å Žåã«ã¯è³å ã®ããã·ã³ãŸãã¯MOPEGâ
SO4ã®éã¯å®è³ªçã«ç¡å€åã§ãã€ãïŒããªãã¡ã
ã®ïŒã€ã®éã¯ãããã14.3ÎŒïœïŒïœããã³117n
ïœïŒïœã§ãã€ãïŒãããããªãããä»ã®ã°ã«ãŒã
ã«å¯Ÿããå®éšã®çµæïŒç¬¬ïŒå³ïŒããæãããªãã
ã«ãè³å ã®ããã·ã³ããã³MOPEGâSO4ã®é
ã¯ãè©Šéšåç©èªäœãšãå¯æ¥ã«é¢é£ãããã®ã§ãã€
ãã 第ïŒå³èšèŒã®çžé¢é¢ä¿ã¯æ¬¡ã®å®éšã§åŸãããã
ã®ã§ãã€ããè€æ°ã®ã°ã«ãŒãã®ã©ããã®åã ã®è ¹
èå ã«ããªã³ïŒ200mgïŒKgïŒããŸãã¯ãè³å åžåæ§
ã«é¢ããŠããã·ã³ãšç«¶åããæ§è³ªãæããã¢ãã
é ž(8)ããŸãã¯ããã·ã³ïŒãšãã«ãšã¹ãã«ã®åœ¢ã®ã
ãã·ã³125mgïŒKgïŒããŸãã¯é£å¡©æ°Žã泚å°ããã30
ååŸã«ãã®ã©ãããã·ã³ã°ã«ã±ãŒãžïŒããïŒã«å ¥
ããŠå¯å·ç°å¢ïŒïŒâïŒäžã«çœ®ãããïŒæéåŸã«è©Š
éšåç©ãå šéšæ®ºãããã®è¡æ¶²å šéšã«ã€ããŠåæã
è¡ã€ãŠããã·ã³ããã³MOPEGâSO4ã®éã枬å®
ãããå¯Ÿç §åç©ã«ã¯é£å¡©ã泚å°ããã·ã³ã°ã«ã±ãŒ
ãžã«å ¥ããŠå®€æž©ïŒ22âïŒã«ãããŠ90åéä¿ã€ãã
ã°ã©ãäžã®åç¹ã¯ïŒã€ã®è³ã®äžã«ååšããããã·
ã³ããã³MOPEGâSO4ã®éãè¡šããããããã®
ããŒã¿ã¯ãè¥å¹²ã®å®éšçµæãéèšããŠç®åºããã
ãã®ã§ãã€ãã宀枩ã«ãããŠé£Œè²ãããè©Šéšåç©
ã®è³å ã®ããã·ã³ããã³MOPEGâSO4ã®éã¯ã
ããã14.6ÎŒïœããã³80nïœïŒïœã§ãã€ãã第ïŒå³
ã®ã°ã©ãã«ãããŠãåèšå·ã¯æ¬¡ã®æå³ãæããïŒ
é»äžžââããªã³ã§ååŠçãããåç©ã«ããã枬å®
å€ïŒçœäžžââé£å¡©æ°Žã§ååŠçãããåç©ã«ããã
枬å®å€ïŒçœãåè§ââããã·ã³ã§ååŠçãããå
ç©ã«ããã枬å®å€ã è³å ã®ããã·ã³ã®éã®ççåŠçãã©ããããŸ
ãããã«ãšããããªã³ã®åæéããã³ã¿ãŒã³ãªãŒ
ããŒéïŒããã¯ãMOPEGâSO4ã®éã®æž¬å®ã«ã
ã枬å®ã§ããïŒã«åœ±é¿ãäžãããã®ã§ãããã©ã
ããã¿ãããã«ã次ã®å®éšãè¡ã€ããããªãã¡ã
å¯å·ç°å¢äžã«çœ®ããè©Šéšåç©ã«ãããäžèšã®ä»£è¬
ç£ç©ã®èç©éã調ã¹ãæäœããããã·ã³ã®éãé«
ãããšæãããåçŽé£ŒæïŒsingle mealïŒãé£ã¹
ãããåŸã«è¡ã€ãã ïŒæ©äžçµ¶é£ãããè©Šéšåç©ã«ç¡èçœé£ŒæïŒã«ãŒ
ã€ã³ïŒïŒ ïŒãŸãã¯40ïŒ ã«ãŒã€ã³é£Œæãåå10æã
ãåå11æãŸã§ã®æéã«ããã€ãŠäžãã次ãã§è©Š
éšåç©ãå¯å·ç°å¢ïŒïŒâïŒäžã«ïŒæéä¿ã¡ã次ã
ã§ããã殺ãããã®è³ãåæããŠããã·ã³ããã³
MOPEGâSO4ã®éã枬å®ããã絶é£ãããå¯Ÿç §
åç©ã¯ããã®ïŒæéã«ããã€ãŠå®€æž©ïŒ22âïŒã«ã
ããŠä¿ã€ãã 絶é£ãããã©ãããå¯å·ç°å¢äžã«ä¿ã€ããšã«ã
ãããã®è³å ã®MOPEGâSO4ã®èç©ãä¿é²ã§
ãããã®éã¯123nïœïŒ22âã«ãããŠä¿ããã絶
é£å¯Ÿç §åç©ïŒãã163nïœã«å¢å ããïŒïŒ°ïŒ0.05ãã
ãã®åŠçã¯è³å ã®ããã·ã³ã®éã«ã¯å šã圱é¿ãäž
ããªãã€ãïŒ10.1ÎŒïœïŒïœå¯Ÿ10.5ÎŒïœïŒïœïŒãå¯å·
ç°å¢äžã«çœ®ãããåç©ã®ãã¡ã§ãïŒïŒ ã«ãŒã€ã³é£Œ
æãŸãã¯40ïŒ ã«ãŒã€ã³é£Œæãæäžããåç©ã§ã¯ã
è³å ã®MOPEGâSO4ã®èç©éã40â50ïŒ å¢å ã
ãïŒç¬¬ïŒè¡šïŒïŒ°ïŒ0.01ïŒãïŒïŒ ã«ãŒã€ã³é£Œæãæ
äžããåç©ã§ã¯è³å ã®ããã·ã³ã®éãçŽ40ïŒ å¢å
ãïŒïŒ°ïŒ0.01ïŒãäžæ¹ã40ïŒ ã«ãŒã€ã³é£Œæãé£ã¹
ãåç©ã§ã¯è³å ã®ããã·ã³ã®éã77ïŒ å¢å ãã
ïŒïŒ°ïŒ0.01ïŒã ç¡èçœè³ªé£Œæã®æäžãè³å ã®ããã·ã³ã®éã®å¢
å ããããããªãã€ãå Žåã«ã¯ãè³å ã®MOPEG
âSO4ã®éããŸãå¢å ããªãã€ãïŒç¬¬ïŒè¡šïŒãã
ã®å®éšã«ãããŠãèçœè³ªãæäžããåç©ã§ã¯è³å
ã®ããã·ã³ã®éãçŽ50ïŒ å¢å ãïŒããªãã¡ã
13.4ÎŒïœïŒïœãã19.5ÎŒïœïŒïœã«å¢å ããïŒïŒ°ïŒ
0.01ïŒããã€ããã«äžŠè¡ããŠè³å ã®MOPEGâSO4
ã®éãå¢å ããã ãããã®å®éšããŒã¿ãŒããæãããªããã«ãã
ãããã·ãã§ååŠçããããŸãã¯å¯å·ç°å¢äžã«çœ®
ããã©ããã§ã¯ãè³å ã®ããã·ã³ã®éãå¢å ãã
ãåŠçãè¡ãããšã«ãããè³å ã®ãã«ãšããããª
ã³ã®ä»£è¬ç£ç©ã§ããMOPEGâSO4ã®èç©éãå¢
å ãããããšãã§ããã®ã§ããããã®ãããªåŠç
ã¯è¬çåŠçåŠçïŒããªãã¡ãããã·ã³ã®è ¹èå 泚
å°ïŒãŸãã¯ççåŠçåŠçïŒããªãã¡ãé«èçœè³ªé£Œ
æã®æäžïŒã§ãã€ãŠããããããã®åŠçã¯ãè³å
ã®ããã·ã³æ¿åºŠã«é¢ããŠããã®åºè³ªïŒãµãã¹ãã¬
ãŒãïŒã®ããã®ããã·ã³ããããã·ã©ãŒãŒã®é«Km
æ§ã«å¹æµããå¹æãäžãããã®ã§ããããã®é µçŽ
ã¯ãåºè³ªã«ã€ããŠå¶éæ¡ä»¶ããããšããæ¬ ç¹ãæ
ããããªããªãã°ããã®é µçŽ ã掻æ§åããããšã
ã«ããã®æŽ»æ§ãããã®ã³ãã¢ã¯ã¿ãŒã«å¯Ÿãã芪å
æ§ãéžæçã«é«ããããã§ããã MOPEGâSO4ã¯ã©ããã®è³å ã«ããããã«ãš
ããããªã³ã®äž»ä»£è¬ç£ç©ã§ãã€ãŠãããã¯ããã
ããã·ãã«ææãªã¡ã«ããºã ã«ããè³å€ã«éã³åº
ããããããããã·ãã®æäžåŸã«ã¯MOPEGâ
SO4ã¯ã©ããã®è³å ã«ãå°ããšã60åéã«ããã€
ãŠãæéã«çŽç·çã«æ¯äŸããéçå²åã§èç©ã
ãããã®æéã®éã¯è³å ã®ãã«ãšããããªã³ã®é
ã¯äžå€ç¶æ ã®ãŸãŸä¿ãããŠãããããMOPEGâ
SO4ã®èç©çïŒèç©éïŒã¯ããã«ãšããããªã³ã®
åæçã瀺ãæçšãªææšãšããŠåœ¹ç«ã€ãã®ã§ã
ãããã®èç©çã¯ãã¹ãã¬ã¹ãäžããã«ãããã
ã·ãåŠçãè¡ã€ãã©ããã®å Žåã«ã¯ãå¯å·ç°å¢äž
ã«çœ®ãããã©ããã®å Žåãããæããã«äœãã€ã
ïŒç¬¬ïŒè¡šããã³ç¬¬ïŒè¡šïŒãããããªãããã©ããã
ãã®ïŒã€ã®ç°å¢ã®ãã¡ã®ãããã®ç°å¢ã®ããšã§çœ®
ããå Žåã§ããäžèšã®èç©çã¯è³å ã®ããã·ã³ã®
éã«å·Šå³ãããå€ã§ããã
ãè¡šã
ãè¡šã
泚ïŒïŒâïŒå¹ã®ã©ãããïŒã°ã«ãŒããšããè€é¡
ã®ã°ã«ãŒãã®ã©ãããïŒæ©äžé£Œæãäžããã次ã
ã§è©Šéšé£Œæã®ãã¡ã®ïŒã€ãåå10æã«äžãããå
å11æããããã®è©Šéšåç©ãïŒâã®å¯å·ç°å¢ã®å®€
ã«ïŒæéå ¥ãããæ£åã«ãã®è©Šéšåç©ã殺ããã
ã®è³å šäœãåæããŠããã·ã³ããã³MOPEGâ
SO4ã®éã枬å®ãããå®éšã§ã¯ãè©Šéšåç©ã¯ç¡
èçœè³ªé£ŒæãŸãã¯40ïŒ èçœè³ªé£Œæããããã9.7
ïœãŸãã¯10.5ïœæ¶è²»ããå®éšã«ããããããã®
飌æã®æ¶è²»éã¯ãããã6.2ïœãŸãã¯8.0ïœã§ãã€
ãããã®ããŒã¿ã¯ã±SEMã®å¹³åå€ãšããŠç®åºã
ãããã®ã§ãã€ãã äŸ ãã®å®æœäŸã¯ãè³å ã®ããã·ã³ã®éãå¢å ãã
ãããšã«ããè³å ã®ãããã³æŸåºéãå¢å ã§ãã
ããšãäŸç€ºãããã®ã§ããã ãã®ããã·ã³ã®ååšéã®å€å°ãã«ãã³ãŒã«ã¢ã
ã³ç¥çµäŒéç©è³ªã®ã·ããã¹å æŸåºéã«åœ±é¿ãäžã
ããã®ã§ãããã©ãããã¿ãããã«ãè©Šéšåç©ã®
è³å ã«ããããããã³ä»£è¬ç£ç©ã§ãããã¢ãããª
ã³é žïŒHVAïŒã®èç©éã«åãŒãããã·ã³æäžã®
圱é¿ã調ã¹ãããã®å®éšã¯ãããããã·ãïŒè³è
é«æ¶²ããã®ææ©é žã®éžåºãé²æ¢ããååç©ïŒã¹ã
ã¯ã¿ãŒããã³ããŒã¬ã³ãŸãŒã1974幎ïŒãŸãã¯ãã
ããªããŒã«ïŒäžæ¢ãããããŒãžã³ã°ã¬ã»ãã¿ãŒã
éå¡ããäœçšãæããå»è¬ïŒãŠã³ã¬ãŒã¹ããã
çã1969幎ïŒã§ååŠçãããè©Šéšåç©ãçšããŠè¡
ã€ããè³å ã®ããã·ã³ã®éãå¢å ãããããšã«ã
ããããããªããŒã«åŠçåç©ã§ã¯è³å ã®HVAè
ç©ãä¿é²ãããããããããã·ãåŠçåç©ã§ã¯è©²
HVAèç©ã¯ä¿é²ãããªãã€ãã äœé150â200ïœã®ãªã¹ã®ã¹ãã©ã°ãŒâããŠã¬ãŒ
ã©ããããã€ãŒã«ããªããŒãããªãŒãžã³ã°ãã©ã
ã©ããªãŒãºïŒãŠã€ã«ãã³ã°ãã³ãMAïŒããäŸçµŠ
ããããã®ãã«ååïŒæããååŸïŒæãŸã§ã®éã
å ç·ç §å°ãè¡ããããã¿ã©ã€ããïŒãºããŠãŒãã¹
ããã³ã³ãããŒïŒããŒã¹ãããŒã²ã³ãN.J.ïŒè£œã®
ãã®ãããããŠãããã°ãã¬ãããã©ããããã€
ãŠãïŒãã€ãŒã«ã¹ããªããŒãããªãŒãžã³ã°ãã©ã
ã©ããªãŒè£œã®é£ŒæïŒããã³æ°Žãèªç±ã«äžãããè¬
åã¯è ¹èå ã«ïŒmlïŒKgïŒäœéïŒã®æ³šå°éïŒå®¹ç©ïŒ
ã§æ³šå°ãããããããªããŒã«ãšããŠãå¯æº¶æ§ãã
ããªããŒã«è£œå€ãããã¯ãã€ã«ãã©ãã©ããªãŒãº
ïŒã©ããžãšã©ãCAïŒè£œã®ããã«ããŒã«ãããæäž
ãããããã·ã³ããã³ããããã·ããã·ã°ããã±
ãã«ã«ãã³ã³ãããŒïŒã»ã³ãã«ã€ã¹ãMOïŒè£œã®
ãã®ãã¯1NâNaOHã«æº¶è§£ãããããŠPH10.0ã«
調ç¯ãããå¯Ÿç §åç©ã«ã¯ãæå®ã®åžéå€ã®ã¿ãæ
äžãããããã·ã³ïŒ100mgïŒKgïŒãŸãã¯ãã®åžé
ç©ã泚å°ããŠãã20ååŸã«ããã®åç©ã«ããããª
ããŒã«ïŒïŒmgïŒKgïŒãŸãã¯ããããã·ãïŒ200
mgïŒKgïŒãæäžããã70ååŸã«ãã®åç©ãéŠéšå
æã«ãã殺ãããè³ãéããã«é€å»ããç·ç¶äœ
ïŒã¹ããªã¢ã¿ïŒãåéããŠååºãïŒã°ããŠã€ã³ã¹
ããŒããã³ã€ããŒãœã³ã®æ¹æ³ã1966幎ïŒããã©ã€
ã¢ã€ã¹ã§åçµããã次ãã§HVAãå®éãããæ®
ãã®è³ã®ãã¢ãžããŒããçšããŠããã·ã³ãå®éã
ãïŒã¯ãŒã«ãŒããã³ãŠãŒãã³ãã¬ã³ãã®æ¹æ³ã
1957幎ïŒãåèšã®æ®åè³ãã¢ãžããŒãè©Šæäžã®ã
ãã·ã³ã®æ¿åºŠãåèšç·ç¶äœã®ãã¢ãžããŒãäžã®ã
ãã·ã³ã®æ¿åºŠãšåæ§ãªå€ã§ãããã©ããã確èªã
ãããã«ãåã°ã«ãŒãããã®ïŒå¹ã®åŠçåç©ïŒã
ã®ãã¡ã®è¥å¹²ã®åç©ã¯ãããã·ã³ããã³ïŒãŸãã¯
ããããªããŒã«ãæäžãããã®ã§ãã€ãïŒã«ã€ã
ãŠæ¯èŒãããšãããããã·ã³æ¿åºŠã®å®è³ªçãªå·®ç°
ã¯å šãèŠåºãããªãã€ãã ããã·ã³ããããã·ã©ãŒãŒã®æŽ»æ§ã¯ããŠãšã€ã
ã€ã¢çã®æ¹æ³ïŒ1971幎ïŒã®å€æ³ã«åŸã€ãŠèª¿ã¹ãã
ããªãã¡ãç·ç¶äœããã®10åéïŒå®¹ç©åäœïŒã®
0.05Mâããªã¹ã¢ã»ããŒãç·©è¡æ¶²ïŒPH6.0ïŒã®äž
ã§ãã¢ãžãã€ãºããããã®ç·©è¡æ¶²ã¯ãããªãã³â
â100ããããŒã¬ã³ç€ŸïŒãã€ã©ãã«ãã€ã¢ã
PAïŒãã0.2ïŒ å«ããã®ã§ãã€ããããããŠåŸã
ãããã¢ãžããŒãã«é å¿åé¢æäœã10000ïœã«ã
ããŠ10åéè¡ã€ãããã®äžæŸæ¶²ãéããŠå®éåæ
ãè¡ã€ãïŒã³ã€ã«ã®æ¹æ³ã1972幎ïŒããã®å Žåã®
å®éçšåªè³ªã®å šå®¹ç©ã¯110ÎŒã§ããããããŠã
ã®äžã«æ¬¡ã®ãã®ãå«ãŸããŠããïŒäžæŸæµäœ50ÎŒ
ïŒDMPH4ïŒããªãã¡ïŒâã¢ããâïŒâããã
ãã·âïŒïŒïŒâãžã¡ãã«âïŒïŒïŒïŒïŒïŒïŒâãã
ã©ããããããªãžã³ãã€ããã¯ãã©ã€ãïŒãã«ã«
ãã€ãªã±ã 瀟ïŒãµã³ãžãšãŽãCAïŒè£œã®ãã®ã
65nmolïŒããªãããµã«ãã¹ããšãŒã29ããã¢
ã«ïŒïŒâã¡ã«ã«ãããšã¿ããŒã«ïŒããã¢ã«ïŒã«ã¿
ã©ãŒãŒ240ãŠãããïŒãã¹ããšãŒãç·©è¡æ¶²ïŒPH
6.2ïŒ0.01ããªã¢ã«ïŒãã¿ã®è èãã調補ããã
è³éŠæâã¢ããé žãã«ã«ããã·ã©ãŒãŒïŒã³ã€
ã«ã1972幎ïŒ10ÎŒïŒè©Šæã¯37âã«ãããŠïŒåé
ãã¬ã€ã³ããŠããŒãããã æçµæ¿åºŠ0.1mMã®å®éçšåªè³ªã«ïŒ¬âïŒâ14Câ
ããã·ã³ïŒæ¯æŽ»æ§åºŠ0.90ÎŒCiïŒmmolïŒ10ÎŒãæ·»
å ãããããŠãã®è©Šæã37âã«ãããŠ30åéã€ã³
ããŠããŒãããããšã«ããåå¿ãéå§ããããã
ã®å®éã10ïŒ ããªã¯ããé ¢é ž0.5mlã®æ·»å ã«ãã
åæ¢ããããã®é žæ§ååªè³ªãå ¶åŸã«ïŒæéãããš
ãããŠ14CO2ãååããããã®14CO2ã¯ãNCSâ
çµç¹æº¶è§£å€0.2mläžã«çœ®ãããçŽçïŒæãéã
ããã®ïŒã«ãã©ããããããåèšæº¶è§£å€ã¯ã¢ããŒ
ã·ã€ã ïŒãµãŒã«ïŒã¢ãŒãªã³ã°ãã³ããã€ããILïŒ
補ã®ãã®ã§ãã€ãã次ãã§ãã®çŽçããã¢ã¯ã¢
ãŸã«10miãå«ãã·ã³ãã¬ãŒã·ãšã³ãã€ã¢ã«ãã
ãŠãŒãã€ã³ã°ã©ã³ããããŠã¯ãªã¢ç€ŸïŒãã¹ãã³ã
MAïŒè£œã®ãã®ãã«ç§»ããŠãã®æŸå°èœã枬å®ã
ãããã©ã³ã¯ïŒç©ºè©ŠéšïŒã§ã¯ã沞隰äžæŸæ¶²ãŸãã¯
ã¢ããšãŒãããã·ã³ïŒ0.2mMïŒãå«ãå®å šå®é
æ··åç©ã䜿çšãããäž¡æ¹ã®æ¹æ³ã«ãããŠãåæ§ãª
çµæãåŸãããã ããã·ã³æäžã«ãããããããªããŒã«åŠçã©ã
ãã®ç·ç¶äœå ã®HVAèç©éãèããå¢å ãã
ïŒ59ïŒ å¢å ïŒïŒ°ïŒ0.001ïŒïŒç¬¬ïŒå³ïŒãããããªã
ããããããã·ãåŠçåç©ã®å Žåã«ã¯ãè³å ã®ã
ãã·ã³ã®éãåœéå€ãŸã§å¢å€§ãããå Žåã§ããã
HVAèç©éã¯å€åããªãã€ãïŒç¬¬ïŒå³ïŒããã
ããªããŒã«ãæäžããã©ããã§ã¯ãç·ç¶äœå ã®
HVAã®æ¿åºŠãšè³å ã®ããã·ã³ã®æ¿åºŠãšã®éã«å¯
æ¥ãªçžé¢é¢ä¿ãèªããããïŒïœïŒ0.70ïŒïŒ°ïŒ
0.01ïŒïŒç¬¬ïŒå³ïŒãäžæ¹ãããããã·ããæäžãã
åç©ã§ã¯ããã®ãããªçžé¢é¢ä¿ã¯å šãèªããããª
ãã€ãã ããããã·ããæäžããã©ããã§ã¯è³å ã®ãã
ã·ã³ã®éãå€åãããããšã«ããHVAãèç©ã
ãããšïŒããã³ãããã«ãã€ãŠãããã³ãçæã
ããããšïŒã¯ã§ããªããããã®ããšããããã®å Ž
åã«ã¯ã¬ã»ãã¿ãŒäŒéåãã€ãŒãããã¯æ©æ§ãäœ
åããŠããã®ããã«ç·ç¶äœå ã®ãããã³ã¬ã»ãã¿
ãŒã®æŽ»æ§åæ©æ§ããããã³åææå¶æ©æ§ãšçµã³ã€
ãããã«ãHVAã®èç©ããã³ãããã³ã®çæã¯
è¡ãããªãã®ã§ãããšæãããã ããªãã¡ããã®å Žåã«ã¯ãããã·ã³æäžã«ã
ããããããã·ãæäžåç©ã®ç·ç¶äœã®åæéãã
ã³æŸåºéãæåã®ãã¡ã¯å¢å€§ããããå ¶åŸã«ãã
ãã³ã¬ã»ãã¿ãŒã®æŽ»æ§ãå¢å€§ãããã®ãã€ãŒãã
ãã¯äœçšã«ãããããã³ã®çæéãæžå°ãããã®
ãããã³çæéã®äœäžãHVAã®çæéã®äœäžã
æãã®ã§ãããšæããããäžæ¹ãããããªãŸãŒã«
åŠçåç©ã§ã¯äžèšã®ãã€ãŒãããã¯æ©æ§ïŒãã
ãããã®æ©æ§ã¯æšå®æ©æ§ã§ããïŒãäœåãããã
ã®ããã«ããã·ã³ã®éãããŒããã³ã®åæéã«åœ±
é¿ãäžãããã®åœ±é¿ã¯çµ¶ããç¶ããããŒããã³ã®
æŸåºãä¿é²ãããåŸã§ããäžèšã®åœ±é¿ã絶ããç¶
ãã®ã§ãããšæãããã ããããã·ãåŠçã©ããã§ã¯ããããžã³ããã
ãã·ã©ãŒãŒã®åååŠçæ§è³ªïŒkinetic propertiesïŒ
ã®ããŒãããã¯åå€åããã€ãããã«ãããã·ã³
æäžãç·ç¶äœå ã®HVAã®èç©ããããããªãã®
ã§ãããšãã仮説ã®çåœã確èªããããã«ãæã
ã¯ãæã ã®å®éšã°ã«ãŒãã®åã ããæäŸãããå
ç©è³è©Šæã«ã€ããŠãããã·ã³ããã³ãã®ãããªã³
âã³ãã¢ã¯ã¿ãŒã«å¯Ÿããåèšé µçŽ ã®èŠªåæ§ã調ã¹
ããè©Šéšç®¡è©Šéšã§ã¯ãããã·ã³ã®åæïŒpriorïŒ
æäžã¯ãDMPH4ã®ããã·ã³ã«å¯Ÿããããã·ã³ã
ãããã·ã©ãŒãŒã®Kmsã«ã¯åœ±é¿ãäžããªãã€ãã
æ¢è¿°ã®åŠãïŒãžãã³ããã¯çã1974幎ïŒãžãã³ã
ãã¯ããã³ã°ã€ãããã1974幎ïŒãããããªããŒ
ã«ã®æäžã¯DMPH4ã«å¯Ÿããè©²é µçŽ ã®Kmã®äœäžã
ãããããã®ã§ããïŒç¬¬ïŒè¡šïŒã 第ïŒå³ã¯ãããããªããŒã«ãŸãã¯ããããã·ã
ãæäžããã©ããã®ç·ç¶äœäžã®HVAèç©éã«å
ãŒãããã·ã³æäžã®åœ±é¿ãå ·äœçã«ç€ºãããã®ã§
ãããã©ããã«ããã·ã³ïŒ100mgïŒKgïŒãŸãã¯ã
ã®åžéå€ãæäžãããã®20ååŸã«ããããªããŒã«
ïŒïŒmgïŒKgïŒãŸãã¯ããããã·ãïŒ200mgïŒKgïŒã
æäžãã第ïŒåç®ã®æ³šå°ãè¡ã€ãŠãã70ååŸã«ã
ã®ã©ããã殺ããåææäœãè¡ãããã®çµæã第
ïŒå³ã®ã°ã©ãã«ç€ºããã第ïŒå³ã«ã¯ãããããªã
ãŒã«ãæäžããè©Šéšåç©ã®ããŒã¿ãŒã¯çœäžžã§ç€º
ããããããªããŒã«ãšããã·ã³ãšã®äž¡è ãæäžã
ãè©Šéšåç©ã®ããŒã¿ãŒã¯é»äžžã§ç€ºãããããããª
ããŒã«ãæäžãããã¹ãŠã®è©Šéšåç©ã§ã¯ãç·ç¶äœ
å ã®HVAã®éãšè³å ã®ããã·ã³ã®éãšã®éã«å¯
æ¥ãªçžé¢é¢ä¿ãèªããããïŒïœïŒ0.70ïŒïŒ°ïŒ
0.01ïŒããããšã¯å¯Ÿç §çã«ãããããã·ãã®ã¿ã
æäžããè©Šéšåç©ïŒïœïŒ17ïŒã®ç·ç¶äœå ã®HVA
ã®éã¯ãããããã·ããšããã·ã³ãšã®äž¡è ãæäž
ããè©Šéšåç©ïŒïœïŒ11ïŒã«ãããHVAã®éãšå€§
äœåãã§ãã€ããåã°ã«ãŒãã«ãããè³å ã®ãã
ã·ã³æ¿åºŠããã³ç·ç¶äœäžã®HVAæ¿åºŠã¯ãããã
次ã®éãã§ãã€ãïŒããããã·ãæäžã°ã«ãŒã
17.65±1.33ÎŒïœïŒïœããã³1.30±0.10ÎŒïœïŒïœïŒã
ãããã·ãïŒããã·ã³æäžã°ã«ãŒã44.06±3.91ÎŒ
ïœïŒïœããã³1.31±0.11ÎŒïœïŒïœïŒããããªããŒ
ã«æäžã°ã«ãŒã17.03±0.97ÎŒïœïŒïœããã³2.00±
0.10ÎŒïœïŒïœïŒããããªããŒã«ïŒããã·ã³æäžã°
ã«ãŒã36.02±2.50ÎŒïœïŒïœããã³3.19±0.20ÎŒïœïŒ
ïœã
ã®ã°ã«ãŒãã®ã©ãããïŒæ©äžé£Œæãäžããã次ã
ã§è©Šéšé£Œæã®ãã¡ã®ïŒã€ãåå10æã«äžãããå
å11æããããã®è©Šéšåç©ãïŒâã®å¯å·ç°å¢ã®å®€
ã«ïŒæéå ¥ãããæ£åã«ãã®è©Šéšåç©ã殺ããã
ã®è³å šäœãåæããŠããã·ã³ããã³MOPEGâ
SO4ã®éã枬å®ãããå®éšã§ã¯ãè©Šéšåç©ã¯ç¡
èçœè³ªé£ŒæãŸãã¯40ïŒ èçœè³ªé£Œæããããã9.7
ïœãŸãã¯10.5ïœæ¶è²»ããå®éšã«ããããããã®
飌æã®æ¶è²»éã¯ãããã6.2ïœãŸãã¯8.0ïœã§ãã€
ãããã®ããŒã¿ã¯ã±SEMã®å¹³åå€ãšããŠç®åºã
ãããã®ã§ãã€ãã äŸ ãã®å®æœäŸã¯ãè³å ã®ããã·ã³ã®éãå¢å ãã
ãããšã«ããè³å ã®ãããã³æŸåºéãå¢å ã§ãã
ããšãäŸç€ºãããã®ã§ããã ãã®ããã·ã³ã®ååšéã®å€å°ãã«ãã³ãŒã«ã¢ã
ã³ç¥çµäŒéç©è³ªã®ã·ããã¹å æŸåºéã«åœ±é¿ãäžã
ããã®ã§ãããã©ãããã¿ãããã«ãè©Šéšåç©ã®
è³å ã«ããããããã³ä»£è¬ç£ç©ã§ãããã¢ãããª
ã³é žïŒHVAïŒã®èç©éã«åãŒãããã·ã³æäžã®
圱é¿ã調ã¹ãããã®å®éšã¯ãããããã·ãïŒè³è
é«æ¶²ããã®ææ©é žã®éžåºãé²æ¢ããååç©ïŒã¹ã
ã¯ã¿ãŒããã³ããŒã¬ã³ãŸãŒã1974幎ïŒãŸãã¯ãã
ããªããŒã«ïŒäžæ¢ãããããŒãžã³ã°ã¬ã»ãã¿ãŒã
éå¡ããäœçšãæããå»è¬ïŒãŠã³ã¬ãŒã¹ããã
çã1969幎ïŒã§ååŠçãããè©Šéšåç©ãçšããŠè¡
ã€ããè³å ã®ããã·ã³ã®éãå¢å ãããããšã«ã
ããããããªããŒã«åŠçåç©ã§ã¯è³å ã®HVAè
ç©ãä¿é²ãããããããããã·ãåŠçåç©ã§ã¯è©²
HVAèç©ã¯ä¿é²ãããªãã€ãã äœé150â200ïœã®ãªã¹ã®ã¹ãã©ã°ãŒâããŠã¬ãŒ
ã©ããããã€ãŒã«ããªããŒãããªãŒãžã³ã°ãã©ã
ã©ããªãŒãºïŒãŠã€ã«ãã³ã°ãã³ãMAïŒããäŸçµŠ
ããããã®ãã«ååïŒæããååŸïŒæãŸã§ã®éã
å ç·ç §å°ãè¡ããããã¿ã©ã€ããïŒãºããŠãŒãã¹
ããã³ã³ãããŒïŒããŒã¹ãããŒã²ã³ãN.J.ïŒè£œã®
ãã®ãããããŠãããã°ãã¬ãããã©ããããã€
ãŠãïŒãã€ãŒã«ã¹ããªããŒãããªãŒãžã³ã°ãã©ã
ã©ããªãŒè£œã®é£ŒæïŒããã³æ°Žãèªç±ã«äžãããè¬
åã¯è ¹èå ã«ïŒmlïŒKgïŒäœéïŒã®æ³šå°éïŒå®¹ç©ïŒ
ã§æ³šå°ãããããããªããŒã«ãšããŠãå¯æº¶æ§ãã
ããªããŒã«è£œå€ãããã¯ãã€ã«ãã©ãã©ããªãŒãº
ïŒã©ããžãšã©ãCAïŒè£œã®ããã«ããŒã«ãããæäž
ãããããã·ã³ããã³ããããã·ããã·ã°ããã±
ãã«ã«ãã³ã³ãããŒïŒã»ã³ãã«ã€ã¹ãMOïŒè£œã®
ãã®ãã¯1NâNaOHã«æº¶è§£ãããããŠPH10.0ã«
調ç¯ãããå¯Ÿç §åç©ã«ã¯ãæå®ã®åžéå€ã®ã¿ãæ
äžãããããã·ã³ïŒ100mgïŒKgïŒãŸãã¯ãã®åžé
ç©ã泚å°ããŠãã20ååŸã«ããã®åç©ã«ããããª
ããŒã«ïŒïŒmgïŒKgïŒãŸãã¯ããããã·ãïŒ200
mgïŒKgïŒãæäžããã70ååŸã«ãã®åç©ãéŠéšå
æã«ãã殺ãããè³ãéããã«é€å»ããç·ç¶äœ
ïŒã¹ããªã¢ã¿ïŒãåéããŠååºãïŒã°ããŠã€ã³ã¹
ããŒããã³ã€ããŒãœã³ã®æ¹æ³ã1966幎ïŒããã©ã€
ã¢ã€ã¹ã§åçµããã次ãã§HVAãå®éãããæ®
ãã®è³ã®ãã¢ãžããŒããçšããŠããã·ã³ãå®éã
ãïŒã¯ãŒã«ãŒããã³ãŠãŒãã³ãã¬ã³ãã®æ¹æ³ã
1957幎ïŒãåèšã®æ®åè³ãã¢ãžããŒãè©Šæäžã®ã
ãã·ã³ã®æ¿åºŠãåèšç·ç¶äœã®ãã¢ãžããŒãäžã®ã
ãã·ã³ã®æ¿åºŠãšåæ§ãªå€ã§ãããã©ããã確èªã
ãããã«ãåã°ã«ãŒãããã®ïŒå¹ã®åŠçåç©ïŒã
ã®ãã¡ã®è¥å¹²ã®åç©ã¯ãããã·ã³ããã³ïŒãŸãã¯
ããããªããŒã«ãæäžãããã®ã§ãã€ãïŒã«ã€ã
ãŠæ¯èŒãããšãããããã·ã³æ¿åºŠã®å®è³ªçãªå·®ç°
ã¯å šãèŠåºãããªãã€ãã ããã·ã³ããããã·ã©ãŒãŒã®æŽ»æ§ã¯ããŠãšã€ã
ã€ã¢çã®æ¹æ³ïŒ1971幎ïŒã®å€æ³ã«åŸã€ãŠèª¿ã¹ãã
ããªãã¡ãç·ç¶äœããã®10åéïŒå®¹ç©åäœïŒã®
0.05Mâããªã¹ã¢ã»ããŒãç·©è¡æ¶²ïŒPH6.0ïŒã®äž
ã§ãã¢ãžãã€ãºããããã®ç·©è¡æ¶²ã¯ãããªãã³â
â100ããããŒã¬ã³ç€ŸïŒãã€ã©ãã«ãã€ã¢ã
PAïŒãã0.2ïŒ å«ããã®ã§ãã€ããããããŠåŸã
ãããã¢ãžããŒãã«é å¿åé¢æäœã10000ïœã«ã
ããŠ10åéè¡ã€ãããã®äžæŸæ¶²ãéããŠå®éåæ
ãè¡ã€ãïŒã³ã€ã«ã®æ¹æ³ã1972幎ïŒããã®å Žåã®
å®éçšåªè³ªã®å šå®¹ç©ã¯110ÎŒã§ããããããŠã
ã®äžã«æ¬¡ã®ãã®ãå«ãŸããŠããïŒäžæŸæµäœ50ÎŒ
ïŒDMPH4ïŒããªãã¡ïŒâã¢ããâïŒâããã
ãã·âïŒïŒïŒâãžã¡ãã«âïŒïŒïŒïŒïŒïŒïŒâãã
ã©ããããããªãžã³ãã€ããã¯ãã©ã€ãïŒãã«ã«
ãã€ãªã±ã 瀟ïŒãµã³ãžãšãŽãCAïŒè£œã®ãã®ã
65nmolïŒããªãããµã«ãã¹ããšãŒã29ããã¢
ã«ïŒïŒâã¡ã«ã«ãããšã¿ããŒã«ïŒããã¢ã«ïŒã«ã¿
ã©ãŒãŒ240ãŠãããïŒãã¹ããšãŒãç·©è¡æ¶²ïŒPH
6.2ïŒ0.01ããªã¢ã«ïŒãã¿ã®è èãã調補ããã
è³éŠæâã¢ããé žãã«ã«ããã·ã©ãŒãŒïŒã³ã€
ã«ã1972幎ïŒ10ÎŒïŒè©Šæã¯37âã«ãããŠïŒåé
ãã¬ã€ã³ããŠããŒãããã æçµæ¿åºŠ0.1mMã®å®éçšåªè³ªã«ïŒ¬âïŒâ14Câ
ããã·ã³ïŒæ¯æŽ»æ§åºŠ0.90ÎŒCiïŒmmolïŒ10ÎŒãæ·»
å ãããããŠãã®è©Šæã37âã«ãããŠ30åéã€ã³
ããŠããŒãããããšã«ããåå¿ãéå§ããããã
ã®å®éã10ïŒ ããªã¯ããé ¢é ž0.5mlã®æ·»å ã«ãã
åæ¢ããããã®é žæ§ååªè³ªãå ¶åŸã«ïŒæéãããš
ãããŠ14CO2ãååããããã®14CO2ã¯ãNCSâ
çµç¹æº¶è§£å€0.2mläžã«çœ®ãããçŽçïŒæãéã
ããã®ïŒã«ãã©ããããããåèšæº¶è§£å€ã¯ã¢ããŒ
ã·ã€ã ïŒãµãŒã«ïŒã¢ãŒãªã³ã°ãã³ããã€ããILïŒ
補ã®ãã®ã§ãã€ãã次ãã§ãã®çŽçããã¢ã¯ã¢
ãŸã«10miãå«ãã·ã³ãã¬ãŒã·ãšã³ãã€ã¢ã«ãã
ãŠãŒãã€ã³ã°ã©ã³ããããŠã¯ãªã¢ç€ŸïŒãã¹ãã³ã
MAïŒè£œã®ãã®ãã«ç§»ããŠãã®æŸå°èœã枬å®ã
ãããã©ã³ã¯ïŒç©ºè©ŠéšïŒã§ã¯ã沞隰äžæŸæ¶²ãŸãã¯
ã¢ããšãŒãããã·ã³ïŒ0.2mMïŒãå«ãå®å šå®é
æ··åç©ã䜿çšãããäž¡æ¹ã®æ¹æ³ã«ãããŠãåæ§ãª
çµæãåŸãããã ããã·ã³æäžã«ãããããããªããŒã«åŠçã©ã
ãã®ç·ç¶äœå ã®HVAèç©éãèããå¢å ãã
ïŒ59ïŒ å¢å ïŒïŒ°ïŒ0.001ïŒïŒç¬¬ïŒå³ïŒãããããªã
ããããããã·ãåŠçåç©ã®å Žåã«ã¯ãè³å ã®ã
ãã·ã³ã®éãåœéå€ãŸã§å¢å€§ãããå Žåã§ããã
HVAèç©éã¯å€åããªãã€ãïŒç¬¬ïŒå³ïŒããã
ããªããŒã«ãæäžããã©ããã§ã¯ãç·ç¶äœå ã®
HVAã®æ¿åºŠãšè³å ã®ããã·ã³ã®æ¿åºŠãšã®éã«å¯
æ¥ãªçžé¢é¢ä¿ãèªããããïŒïœïŒ0.70ïŒïŒ°ïŒ
0.01ïŒïŒç¬¬ïŒå³ïŒãäžæ¹ãããããã·ããæäžãã
åç©ã§ã¯ããã®ãããªçžé¢é¢ä¿ã¯å šãèªããããª
ãã€ãã ããããã·ããæäžããã©ããã§ã¯è³å ã®ãã
ã·ã³ã®éãå€åãããããšã«ããHVAãèç©ã
ãããšïŒããã³ãããã«ãã€ãŠãããã³ãçæã
ããããšïŒã¯ã§ããªããããã®ããšããããã®å Ž
åã«ã¯ã¬ã»ãã¿ãŒäŒéåãã€ãŒãããã¯æ©æ§ãäœ
åããŠããã®ããã«ç·ç¶äœå ã®ãããã³ã¬ã»ãã¿
ãŒã®æŽ»æ§åæ©æ§ããããã³åææå¶æ©æ§ãšçµã³ã€
ãããã«ãHVAã®èç©ããã³ãããã³ã®çæã¯
è¡ãããªãã®ã§ãããšæãããã ããªãã¡ããã®å Žåã«ã¯ãããã·ã³æäžã«ã
ããããããã·ãæäžåç©ã®ç·ç¶äœã®åæéãã
ã³æŸåºéãæåã®ãã¡ã¯å¢å€§ããããå ¶åŸã«ãã
ãã³ã¬ã»ãã¿ãŒã®æŽ»æ§ãå¢å€§ãããã®ãã€ãŒãã
ãã¯äœçšã«ãããããã³ã®çæéãæžå°ãããã®
ãããã³çæéã®äœäžãHVAã®çæéã®äœäžã
æãã®ã§ãããšæããããäžæ¹ãããããªãŸãŒã«
åŠçåç©ã§ã¯äžèšã®ãã€ãŒãããã¯æ©æ§ïŒãã
ãããã®æ©æ§ã¯æšå®æ©æ§ã§ããïŒãäœåãããã
ã®ããã«ããã·ã³ã®éãããŒããã³ã®åæéã«åœ±
é¿ãäžãããã®åœ±é¿ã¯çµ¶ããç¶ããããŒããã³ã®
æŸåºãä¿é²ãããåŸã§ããäžèšã®åœ±é¿ã絶ããç¶
ãã®ã§ãããšæãããã ããããã·ãåŠçã©ããã§ã¯ããããžã³ããã
ãã·ã©ãŒãŒã®åååŠçæ§è³ªïŒkinetic propertiesïŒ
ã®ããŒãããã¯åå€åããã€ãããã«ãããã·ã³
æäžãç·ç¶äœå ã®HVAã®èç©ããããããªãã®
ã§ãããšãã仮説ã®çåœã確èªããããã«ãæã
ã¯ãæã ã®å®éšã°ã«ãŒãã®åã ããæäŸãããå
ç©è³è©Šæã«ã€ããŠãããã·ã³ããã³ãã®ãããªã³
âã³ãã¢ã¯ã¿ãŒã«å¯Ÿããåèšé µçŽ ã®èŠªåæ§ã調ã¹
ããè©Šéšç®¡è©Šéšã§ã¯ãããã·ã³ã®åæïŒpriorïŒ
æäžã¯ãDMPH4ã®ããã·ã³ã«å¯Ÿããããã·ã³ã
ãããã·ã©ãŒãŒã®Kmsã«ã¯åœ±é¿ãäžããªãã€ãã
æ¢è¿°ã®åŠãïŒãžãã³ããã¯çã1974幎ïŒãžãã³ã
ãã¯ããã³ã°ã€ãããã1974幎ïŒãããããªããŒ
ã«ã®æäžã¯DMPH4ã«å¯Ÿããè©²é µçŽ ã®Kmã®äœäžã
ãããããã®ã§ããïŒç¬¬ïŒè¡šïŒã 第ïŒå³ã¯ãããããªããŒã«ãŸãã¯ããããã·ã
ãæäžããã©ããã®ç·ç¶äœäžã®HVAèç©éã«å
ãŒãããã·ã³æäžã®åœ±é¿ãå ·äœçã«ç€ºãããã®ã§
ãããã©ããã«ããã·ã³ïŒ100mgïŒKgïŒãŸãã¯ã
ã®åžéå€ãæäžãããã®20ååŸã«ããããªããŒã«
ïŒïŒmgïŒKgïŒãŸãã¯ããããã·ãïŒ200mgïŒKgïŒã
æäžãã第ïŒåç®ã®æ³šå°ãè¡ã€ãŠãã70ååŸã«ã
ã®ã©ããã殺ããåææäœãè¡ãããã®çµæã第
ïŒå³ã®ã°ã©ãã«ç€ºããã第ïŒå³ã«ã¯ãããããªã
ãŒã«ãæäžããè©Šéšåç©ã®ããŒã¿ãŒã¯çœäžžã§ç€º
ããããããªããŒã«ãšããã·ã³ãšã®äž¡è ãæäžã
ãè©Šéšåç©ã®ããŒã¿ãŒã¯é»äžžã§ç€ºãããããããª
ããŒã«ãæäžãããã¹ãŠã®è©Šéšåç©ã§ã¯ãç·ç¶äœ
å ã®HVAã®éãšè³å ã®ããã·ã³ã®éãšã®éã«å¯
æ¥ãªçžé¢é¢ä¿ãèªããããïŒïœïŒ0.70ïŒïŒ°ïŒ
0.01ïŒããããšã¯å¯Ÿç §çã«ãããããã·ãã®ã¿ã
æäžããè©Šéšåç©ïŒïœïŒ17ïŒã®ç·ç¶äœå ã®HVA
ã®éã¯ãããããã·ããšããã·ã³ãšã®äž¡è ãæäž
ããè©Šéšåç©ïŒïœïŒ11ïŒã«ãããHVAã®éãšå€§
äœåãã§ãã€ããåã°ã«ãŒãã«ãããè³å ã®ãã
ã·ã³æ¿åºŠããã³ç·ç¶äœäžã®HVAæ¿åºŠã¯ãããã
次ã®éãã§ãã€ãïŒããããã·ãæäžã°ã«ãŒã
17.65±1.33ÎŒïœïŒïœããã³1.30±0.10ÎŒïœïŒïœïŒã
ãããã·ãïŒããã·ã³æäžã°ã«ãŒã44.06±3.91ÎŒ
ïœïŒïœããã³1.31±0.11ÎŒïœïŒïœïŒããããªããŒ
ã«æäžã°ã«ãŒã17.03±0.97ÎŒïœïŒïœããã³2.00±
0.10ÎŒïœïŒïœïŒããããªããŒã«ïŒããã·ã³æäžã°
ã«ãŒã36.02±2.50ÎŒïœïŒïœããã³3.19±0.20ÎŒïœïŒ
ïœã
ãè¡šã
第ïŒè¡šèšèŒã®ããŒã¿ã¯ã次ã®å®éšã®çµæã瀺ã
ããã®ã§ãããããªãã¡ãããã·ã³ããããã·ã©
ãŒãŒã®æŽ»æ§ã調ã¹ãããã«ç·ç¶äœè©Šæã®å®éãã
ããã·ã³æ¿åºŠã0.125â1.0mMãšããããŠ
DMPH4æ¿åºŠã0.1â0.5mMãšããŠè¡ã€ãã®ã§ã
ããããããªããŒã«ãããã·ã³ãšäžç·ã«ããŸãã¯
äžç·ã«ããã«æäžããè©Šéšåç©ã®å Žåã«ã¯ããã
ããã·ããæäžããè©Šéšåç©ã®å Žåãããã
DMPH4ã«å¯Ÿããããã·ã³ããããã·ã©ãŒãŒã®Km
ã®å€ãèããäœãã€ãïŒïŒ°ïŒ0.001ïŒæ¬ç 究è ã®
ïœâãã¹ãïŒã ããã«ããããã®ããŒã¿ãŒã¯æ¬¡ã®ä»®èšã®æ£åœæ§
ãæ¯æãããã®ã§ãããããªãã¡ãããã·ã³ãã
ããã·ã©ãŒãŒã¯åžžã«çäœäžã§ãã®ã¢ããé žåºè³ªã§
飜åããåŸããã®ãšã¯éãããæèšããã°ãïŒã
ãããªããŒã«ã«ããïŒããŒããã³âã¬ã»ãã¿ãŒã®
éå¡ïŒé®æïŒã®çµæãšããŠããããã³ãéåžžã®å Ž
åãããäžå±€å€ãåæãããããªè³ãæããåç©
ã§ã¯ãããã·ã³ããããã·ã©ãŒãŒã¯åžžã«çäœäžã®
ãã®ã¢ããé žåºè³ªã§é£œåããåŸããã®ãšã¯éããª
ããšãã仮説ã¯æ£åœã§ãããšæããããããã«ãŸ
ããåèšã®ããŒã¿ãã次ã®ããšã容æã«ç解ãã
åŸãã§ããããããªãã¡ãïŒããã·ã³æäžã«ããïŒ
åèšé µçŽ ã®é£œå床ãäžå±€é«ããããšã«ãããã
ããã«ãã³ãŒã«ã¢ããç¥çµäŒéç©è³ªããã³ããã
ã³ã®çæéã®ã¿ãªãã該äŒéç©è³ªã®æŸåºéããŸã
äžå±€å¢å€§ã§ããã®ã§ãããããã·ã³ã«ããããã
ã³ã®åæããã³æŸåºãå¶åŸ¡ããããšã«ãã次ã®ç
æ°ãæ²»çã§ããããªãã¡ããã«ããªããŒã«æäžåŸ
ã®ããŒãã³ãœã³ç ã®åŠãããããããŒãžãã¯ãã€
ãã³ã®è奮ããã°ãã°èµ·ãç æ°ãæ²»çã§ããã®ã§
ããã
ããã®ã§ãããããªãã¡ãããã·ã³ããããã·ã©
ãŒãŒã®æŽ»æ§ã調ã¹ãããã«ç·ç¶äœè©Šæã®å®éãã
ããã·ã³æ¿åºŠã0.125â1.0mMãšããããŠ
DMPH4æ¿åºŠã0.1â0.5mMãšããŠè¡ã€ãã®ã§ã
ããããããªããŒã«ãããã·ã³ãšäžç·ã«ããŸãã¯
äžç·ã«ããã«æäžããè©Šéšåç©ã®å Žåã«ã¯ããã
ããã·ããæäžããè©Šéšåç©ã®å Žåãããã
DMPH4ã«å¯Ÿããããã·ã³ããããã·ã©ãŒãŒã®Km
ã®å€ãèããäœãã€ãïŒïŒ°ïŒ0.001ïŒæ¬ç 究è ã®
ïœâãã¹ãïŒã ããã«ããããã®ããŒã¿ãŒã¯æ¬¡ã®ä»®èšã®æ£åœæ§
ãæ¯æãããã®ã§ãããããªãã¡ãããã·ã³ãã
ããã·ã©ãŒãŒã¯åžžã«çäœäžã§ãã®ã¢ããé žåºè³ªã§
飜åããåŸããã®ãšã¯éãããæèšããã°ãïŒã
ãããªããŒã«ã«ããïŒããŒããã³âã¬ã»ãã¿ãŒã®
éå¡ïŒé®æïŒã®çµæãšããŠããããã³ãéåžžã®å Ž
åãããäžå±€å€ãåæãããããªè³ãæããåç©
ã§ã¯ãããã·ã³ããããã·ã©ãŒãŒã¯åžžã«çäœäžã®
ãã®ã¢ããé žåºè³ªã§é£œåããåŸããã®ãšã¯éããª
ããšãã仮説ã¯æ£åœã§ãããšæããããããã«ãŸ
ããåèšã®ããŒã¿ãã次ã®ããšã容æã«ç解ãã
åŸãã§ããããããªãã¡ãïŒããã·ã³æäžã«ããïŒ
åèšé µçŽ ã®é£œå床ãäžå±€é«ããããšã«ãããã
ããã«ãã³ãŒã«ã¢ããç¥çµäŒéç©è³ªããã³ããã
ã³ã®çæéã®ã¿ãªãã該äŒéç©è³ªã®æŸåºéããŸã
äžå±€å¢å€§ã§ããã®ã§ãããããã·ã³ã«ããããã
ã³ã®åæããã³æŸåºãå¶åŸ¡ããããšã«ãã次ã®ç
æ°ãæ²»çã§ããããªãã¡ããã«ããªããŒã«æäžåŸ
ã®ããŒãã³ãœã³ç ã®åŠãããããããŒãžãã¯ãã€
ãã³ã®è奮ããã°ãã°èµ·ãç æ°ãæ²»çã§ããã®ã§
ããã
第ïŒå³ã¯å®æœäŸèšèŒã®å®éšã®çµæã瀺ããã°
ã©ãã§ããã第ïŒå³ã¯å®æœäŸèšèŒã®å®éšã®çµæ
ã瀺ããã°ã©ãã§ããã
ã©ãã§ããã第ïŒå³ã¯å®æœäŸèšèŒã®å®éšã®çµæ
ã瀺ããã°ã©ãã§ããã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ è³ã·ããã¹ã«ããããããã³åã¯ãã«ãšãã
ããªã³ã®æ¬ ä¹ã«äŒŽãçŸæ£ãæããæ£è ã®è³å ã§ã·
ããã¹ãžã®ãããã³ãŸãã¯ãã«ãšããããªã³ã®æŸ
åºéãå¶åŸ¡ããããã®çµæç©ã§ãã€ãŠãè¡æŒ¿ã¬ã
ã«ã®ããã·ã³ãŸãã¯ããšãã«ã¢ã©ãã³ã®éãå¶åŸ¡
ããŠå¯Ÿå¿éã®ãããã³ããã³ïŒãŸãã¯ãã«ãšãã
ããªã³ãè³å ã§çæãããããã«æå¹ãªéã®ãã
ã·ã³ãããšãã«ã¢ã©ãã³ããŸãã¯ããã·ã³ãšããš
ãã«ã¢ã©ãã³ãšã®æ··åç©ãå«æããäžæ§ã¢ããé ž
補å€ãå«ã¿ãæ£è ïŒKgåœãïŒã200mgã®æè¬éã§
æ£è ã«æäžãããçµæç©ã ïŒ æŽ»æ§ãããã³æŸåºæ§ãã€ãã³ãæãã人äœã«
æäžãããšãã«ãããããŒãžãã¯ç¥çµäŒå°ãå¢å€§
ãŸãã¯äœäžããããäœçšãæããè¬å€ãšã ããã·ã³ãããšãã«ã¢ã©ãã³ããŸãã¯ããã·ã³
ãšããšãã«ã¢ã©ãã³ãšã®æ··åç©ãå«ã¿ããããŠã
ããããŒãžãã¯ç¥çµäŒå°ãå¢å€§ãŸãã¯äœäžããã
çµæãæããäžæ§ã¢ããé žè£œå€ ãšãå«æããããšãç¹åŸŽãšããç¹èš±è«æ±ã®ç¯å²ç¬¬
ïŒé èšèŒã®çµæç©ã ïŒ äººäœã«æäžãããšãã«ãããããŒãžãã¯ç¥çµ
äŒå°ãå¢å€§ãŸãã¯äœäžãããè¬å€ãšã ããã·ã³ãããšãã«ã¢ã©ãã³ããŸãã¯ããã·ã³
ãšããšãã«ã¢ã©ãã³ãšã®æ··åç©ããä»ã®äžæ§ã¢ã
ãé žãšäžç·ã«ããŸãã¯äžç·ã§ãªãå«æãããããŠ
è³å ã®ãã«ãšããããªã³ã®éãå¢å€§ãŸãã¯äœäžã
ããããšãã§ããäžæ§ã¢ããé žè£œå€ ãšãå«æããããšãç¹åŸŽãšããç¹èš±è«æ±ã®ç¯å²ç¬¬
ïŒé ãŸãã¯ç¬¬ïŒé ã«èšèŒã®çµæç©ã
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89874078A | 1978-04-24 | 1978-04-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS54145219A JPS54145219A (en) | 1979-11-13 |
| JPS647044B2 true JPS647044B2 (ja) | 1989-02-07 |
Family
ID=25409977
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP4983079A Granted JPS54145219A (en) | 1978-04-24 | 1979-04-24 | Composition for increasing dopamine and norepinephilin content within neurosynapse |
| JP4983279A Granted JPS557261A (en) | 1978-04-24 | 1979-04-24 | Composition of decreasing quantity of prolactin in serum |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP4983279A Granted JPS557261A (en) | 1978-04-24 | 1979-04-24 | Composition of decreasing quantity of prolactin in serum |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0005058B1 (ja) |
| JP (2) | JPS54145219A (ja) |
| CA (1) | CA1140859A (ja) |
| DE (1) | DE2967257D1 (ja) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0667183U (ja) * | 1993-03-04 | 1994-09-20 | æ¥ç£ãã£ãŒãŒã«å·¥æ¥æ ªåŒäŒç€Ÿ | é»åãã©ãŒã¢ãŒã ã®æ¯æè£ çœ® |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE30210T1 (de) * | 1981-07-15 | 1987-10-15 | Richard J Wurtman | Zusammensetzung zur erhoehung des blutdrucks. |
| US4542123A (en) * | 1982-01-11 | 1985-09-17 | Massachusetts Institute Of Technology | Composition and method for increasing brain tyrosine levels |
| ATE45672T1 (de) * | 1983-05-16 | 1989-09-15 | Massachusetts Inst Technology | Eine pharmazeutische zusammensetzung zum zweck der behandlung einer neurologischen krankheit oder des alterns. |
| US5480865A (en) * | 1994-02-25 | 1996-01-02 | Parkinson's Charitable Trust | Nutritional composition |
| JP2004123564A (ja) * | 2002-09-30 | 2004-04-22 | Inst Of Physical & Chemical Res | äžæ¢æ©èœæ¹åçšã¢ããé žçµæç© |
| CN112924598B (zh) * | 2021-01-28 | 2023-07-28 | 广å·åžåŠå¥³å¿ç«¥å»çäžå¿ | çç©èºç±»ç¥ç»é莚çå®éåææ¹æ³ |
| CN117919232B (zh) * | 2023-11-30 | 2024-10-25 | äžæµ·åžäžæ¹å»é¢ïŒåæµå€§åŠéå±äžæ¹å»é¢ïŒ | å²åäžé žåšæ²»çè硬å以åå ç«æ§èæ䌀çåºçš |
-
1979
- 1979-04-20 EP EP79300650A patent/EP0005058B1/en not_active Expired
- 1979-04-20 DE DE7979300650T patent/DE2967257D1/de not_active Expired
- 1979-04-24 JP JP4983079A patent/JPS54145219A/ja active Granted
- 1979-04-24 CA CA000326257A patent/CA1140859A/en not_active Expired
- 1979-04-24 JP JP4983279A patent/JPS557261A/ja active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0667183U (ja) * | 1993-03-04 | 1994-09-20 | æ¥ç£ãã£ãŒãŒã«å·¥æ¥æ ªåŒäŒç€Ÿ | é»åãã©ãŒã¢ãŒã ã®æ¯æè£ çœ® |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS54145219A (en) | 1979-11-13 |
| EP0005058B1 (en) | 1984-10-17 |
| JPS6326086B2 (ja) | 1988-05-27 |
| CA1140859A (en) | 1983-02-08 |
| EP0005058A3 (en) | 1979-11-14 |
| JPS557261A (en) | 1980-01-19 |
| DE2967257D1 (en) | 1984-11-22 |
| EP0005058A2 (en) | 1979-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4377595A (en) | Process for reducing depression | |
| van Praag et al. | Cerebral monoamines and depression: an investigation with the probenecid technique | |
| Spector et al. | Biochemical and pharmacological effects of the monoamine oxidase inhibitors, iproniazid, 1-phenyl-2-hydrazinopropane (JB 516) and 1-phenyl-3-hydrazinobutane (JB 835) | |
| Pletscher | L. Monoamine oxidase inhibitors | |
| US6635667B2 (en) | Methods of treatment using MAO-A and MAO-B inhibitors such as L-deprenyl | |
| US20180263989A1 (en) | Therapeutic approaches for treating parkinson's disease | |
| RU2125448C1 (ru) | ЀаÑЌаÑевÑОÑеÑÐºÐ°Ñ ÐºÐŸÐŒÐ¿ÐŸÐ·ÐžÑÐžÑ Ðž ÑпПÑПб ее пПлÑÑеМОÑ, ÑпПÑПб леÑÐµÐœÐžÑ ÐœÐ°ÑÑÑеМОй, ÑазвОваÑÑÐžÑ ÑÑ Ð²ÑлеЎÑÑвОе МейÑПЎегеМеÑаÑОвМÑÑ Ð¿ÑПÑеÑÑПв | |
| JPH0138087B2 (ja) | ||
| Aprison et al. | Hypersensitive serotonergic receptors: A new hypothesis for one subgroup of unipolar depression derived from an animal model | |
| JPS647044B2 (ja) | ||
| CA2562035C (en) | Treatment of depressive disorders | |
| US4397866A (en) | Process for increasing glycine levels in the brain and spinal cord | |
| US4435424A (en) | Process for improving vigor and mood in normal human patients | |
| US4190672A (en) | Method and compositions of treating Parkinsonisms with levodopa and 3',4'-dihydroxy-2-methylisopropiophenone | |
| CA2320556A1 (en) | N,n-dichlorinated omega amino acids and uses thereof | |
| Neff et al. | Clozapine modulates aromatic L-amino acid decarboxylase activity in mouse striatum | |
| EP0005333B1 (en) | A pharmaceutical composition comprising an amino acid for reducing blood serum prolactin levels | |
| US4224343A (en) | Process and composition for decreasing blood serum prolactin levels | |
| US4405629A (en) | Process for increasing glycine levels in the brain and spinal cord | |
| CA1156148A (en) | Process for reducing depression | |
| RU2135171C1 (ru) | СÑеЎÑÑвП, акÑОвОÑÑÑÑее ПбЌеМ веÑеÑÑв | |
| MÃŒller et al. | Acyclovir inhibits rat liver tryptophan-2, 3-dioxygenase and induces a concomitant rise in brain serotonin and 5-hydroxyindole acetic acid levels | |
| EP0056401A1 (en) | Process for improving vigor and mood in normal human patients | |
| FR2744121A1 (fr) | Nouveaux derives de 2-chloro-3-arylamino-1-4-naphtoquinone, leur procede de preparation et leur utilisation comme agent pour inhiber l'agregation plaquettaire | |
| HK40123243A (zh) | çšçæ°šé žèœ¬è¿æå¶åæ²»çèæ§ååççç»åç©åæ¹æ³ |